

## Supplementary Information

### Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites

Jianli Tao<sup>1#,\*</sup>, Qi Wang<sup>1#</sup>, Carlos Mendez-Dorantes<sup>2</sup>, Kathleen H. Burns<sup>2</sup>, Roberto Chiarle<sup>1,3\*</sup>

<sup>1</sup>Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA

<sup>2</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA

<sup>3</sup>Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, 10126 Italy

#These authors contributed equally

\*email: [roberto.chiarle@childrens.harvard.edu](mailto:roberto.chiarle@childrens.harvard.edu); [jianli.tao@childrens.harvard.edu](mailto:jianli.tao@childrens.harvard.edu)

The PDF file includes:

Supplementary Figures 1-14

Supplementary Tables 1-5

Supplementary Sequences 1-13

## Supplementary Figures

**Supplementary Figure 1.** CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *MYC* locus in HEK293T cells.

**Supplementary Figure 2.** CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *RAG1* locus in HEK293T cells.

**Supplementary Figure 3.** CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *CCR5* locus in HEK293T cells.

**Supplementary Figure 4.** Development of PolyA-seq to capture genome-wide *de novo* L1-ORFeus insertion events.

**Supplementary Figure 5.** RT-dependent *de novo* L1-ORFeus insertions at CRISPR/Cas9 off-target sites in HEK293T cells.

**Supplementary Figure 6.** Detailed characterization of *de novo* L1-ORFeus insertions at CRISPR/Cas9 target site in HeLa cells.

**Supplementary Figure 7.** RT-dependent *de novo* L1-ORFeus insertions at CRISPR/Cas9 target site in U2OS cells.

**Supplementary Figure 8.** RT-dependent *de novo* L1RP insertions at CRISPR/Cas9 target site in HEK293T cells.

**Supplementary Figure 9.** Safety evaluation of prime editing at the *MYC* (+2-4AAA del) site in HEK293T cells.

**Supplementary Figure 10.** Safety evaluation of prime editing at the *MYC* (+5GtoC) or *FANCF* (+5GtoT) site in HEK293T cells.


**Supplementary Figure 11.** Characterization of PE3 (*MYC* +5GtoC) and PE3 (*FANCF* +5GtoT) editing in HEK293T cells.

**Supplementary Figure 12.** Characterization of *de novo* L1-ORFeus insertions in PE3 edited HEK293T cells.

**Supplementary Figure 13.** *De novo* L1-ORFeus insertions are rare in base editing in HEK293T cells.


**Supplementary Figure 14.** Endogenous L1 sequences found at CRISPR/Cas9 target sites in HEK293T cells.

# Supplementary Figure 1



# Supplementary Figure 1 Continued


## k (continued)










**Supplementary Figure 1. CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *MYC* locus in HEK293T cells.** **a**, Schematic representation of pCEP4 GFP control, L1-ORFeus, L1-ENm and L1-RTm plasmids used in our study. CMV=CMV promoter; ORF=open reading frame; Intron=human gamma globin intron. **b**, Percentage of GFP-positive cells in HEK293T or HeLa cells at the indicated days after transfection of the L1-ORFeus reporter plasmid. Puromycin selection was performed 2 days post-transfection, and GFP-positive cells were analyzed by flow cytometry. **c-g**, Experiments were performed as shown in **Fig. 1b**, then GFP-positive HEK293T cells were analyzed at day 11 (**c**) or at day 6 or day 11 (**d**). Data are Mean $\pm$ SD, n=3 independent experiments. The PCR assay across the intron of the GFP reporter gene (Intron assay) was performed at day 11. Splicing of the artificial intron from GFP results in a shorter PCR product (from 1192 bp to 292 bp) (**e**, bottom); blue and red arrows indicate the forward or reverse primer, respectively (**e**, top). RT-PCR was performed to analyze the RNA levels of ORF1 and ORF2 at day 2 (**f**). Western Blot was performed to detect L1 ORF1p protein (along with other indicated cell lines) (**g**); the relative expression of the ORF1p protein was measured by densitometry using Image J. **h**, Editing efficiency of CRISPR/Cas9 at the *MYC* target site in HEK293T cells. Data are Mean $\pm$ SD, n=4 independent experiments. **i**, Top: Schematic design of improved amplicon sequencing at *MYC* locus. Bottom: to reduce background from uncut or small indels (i.e. the strong PCR band), we enrich the insertion events by gel excision between 300 bp to 1 kb. **j**, Numbers of insertions mapped to the human genome (**j**, left) or lentiCRISPR v2 plasmid (**j**, right) obtained by amplicon sequencing at the *MYC* locus targeted by *MYC* CRISPR/Cas9 in HEK293T cells expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. **k,l**, Numbers and fragment lengths of lentiCRISPR v2 plasmid insertions (**k**) or chromosome 8 insertions (**l**) obtained by amplicon sequencing at the *MYC* locus in HEK293T cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. Source data are provided as a Source Data file.

## Supplementary Figure 2




# Supplementary Figure 2 Continued

## g (continued)



**Supplementary Figure 2. CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *RAG1* locus in HEK293T cells.** **a,b**, Percentage of GFP-positive HEK293T cells at day 6 or day 11 after L1-ORFeus transfection and introducing CRISPR/Cas9-mediated DSBs at the *RAG1* locus (**a**) (Data are Mean±SD, n=3 independent experiments). Intron assay was performed to probe the L1-ORFeus retrotransposition events by genomic DNA-PCR at day 11 (**b**). **c**, Editing efficiency of CRISPR/Cas9 at the *RAG1* target site in HEK293T cells expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. Data are Mean±SD, n=5 independent experiments. **d**, Pie charts show the relative abundance of three main types of insertions (i.e., L1-ORFeus, lentiCRISPR v2 plasmid and genomic fragments) obtained by amplicon sequencing at the *RAG1* locus in HEK293T cells targeted by *RAG1* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. **e**, Numbers of insertions mapped to the human genome (**e**, left) or lentiCRISPR v2 plasmid (**e**, right) obtained by amplicon sequencing at the *RAG1* locus in HEK293T cells targeted by *RAG1* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. **f-h**, Numbers and fragment lengths of L1-ORFeus insertions (**f**), lentiCRISPR v2 plasmid insertions (**g**) or chromosome 11 insertions (**h**) obtained by amplicon sequencing at the *RAG1* locus in HEK293T cells targeted by *RAG1* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. Example L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the *RAG1* CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus are shown in **Supplementary Sequence 7**. **i**, Similar to **Fig. 2b**, L1-ORFeus junction analysis obtained by amplicon sequencing at the *RAG1* locus targeted by *RAG1* CRISPR/Cas9 in HEK293T cells expressing L1-ORFeus. Source data are provided as a Source Data file.


# Supplementary Figure 3



**Supplementary Figure 3. CRISPR/Cas9 facilitates *de novo* L1-ORFeus insertions at the *CCR5* locus in HEK293T cells.** **a,b**, Percentage of GFP-positive HEK293T cells at day 6 or day 11 after L1-ORFeus transfection and introducing CRISPR/Cas9-mediated DSBs at the *CCR5* locus (**a**) (Data are Mean $\pm$ SD, n=3 independent experiments), Intron assay was performed by genomic DNA-PCR at day 11 (**b**). **c**, Editing efficiency of CRISPR/Cas9 at the *CCR5* target site in HEK293T cells expressing L1-ORFeus or L1-RTm. Data are Mean $\pm$ SD, n=4 independent experiments. **d**, Pie charts show the relative abundance of three main types of insertions (i.e., L1-ORFeus, lentiCRISPR v2 plasmid and genomic fragments) obtained by amplicon sequencing at the *CCR5* locus in HEK293T cells targeted by *CCR5* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. **e,f**, Numbers of insertions mapped to LINE-1 (ORFeus) (**e**), the human genome (**f**, left) or lentiCRISPR v2 plasmid (**f**, right) obtained by amplicon sequencing at the *CCR5* locus in HEK293T cells targeted by *CCR5* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. **g,h**, Numbers and fragment lengths of L1-ORFeus insertions (**g**) or lentiCRISPR v2 plasmid insertions (**h**) obtained by amplicon sequencing at the *CCR5* locus in HEK293T cells targeted by *CCR5* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. Example L1-ORFeus insertion bridging the intron of GFP obtained by amplicon sequencing at the *CCR5* CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus are shown in **Supplementary Sequence 8**. The only L1-ORFeus insertional sequence obtained by amplicon sequencing at the *CCR5* CRISPR/Cas9 target site in HEK293T cells expressing L1-RTm is shown in **Supplementary Sequence 10**. The orientation of insertions is shown in orange when the fragment is oriented 5' to 3' (+) or blue when 3' to 5' (-). Source data are provided as a Source Data file.

# Supplementary Figure 4

**a**




**b**

```


eGFP {
AGTTGCCGTCGCTCTGAAGAAGTGGTGCCTCTGGACGTAGCCTCGGGCATGGCGGACTGAAGAAGTCGT
GCTGCTTCTATGTGGTCGGGGTAGCGGCTGAAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTGGCCAG
GGCACGGGCAGCTTCCCGTGGTGCAGATGAACCTCAGGGTCAGCTTCCCGTAGGTGGCATCGCCCTCGCCCTCG
CCGGACAGCTGAACTTGTGGCGTTTACGTCCCGTCCAGCTCGACCAAGGATGGCACCACCCGGTGAACAGC
TCCTCGCCCTTGTCTACCATTGGTGGCAATTGGAAGCTTGGAGCTCGAGCTGAGTCCGGTAGCGCTAGCGGATCT
CMV promoter {
GACGGTTCCTAAACAGCTCTGCTTATATAGACCTCCACCGTACACGCCTACCGCCATTGCGTCAATGGGGC
GGAGTGTGTACGACTTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAACTCCCATTGACGTCATGGGGTGG
AGACTTGGAAATCCCGTGGTGCAGTCAAACCGCTATCCACGCCATTGATGACTGCCAAAACCGCATCACCATGGTAA
TAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCCATAAAGTCAATGACTGGGCATAATGCCAGG
CGGGCCATTTACCGTATTGACGTCATAGGGGGCGTACTTGGCATATGATACACTTATGATGACTGCCAAGTGGGC
AGTTTACCGTAAATACTCCACCATTGACGTCATGGAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTA
TTGACGTCATGGCGGGGGTCTTGGGCGGTGACCCAGGCGGGCCATTACCCTAAGTTATGTAACCGGGAAC
TCCATATATGGGCTATGAACATGACCCCGTAATTGATTACTATTAGCCGGGCAATGTGCACATGTACCCCTAAA
SV40 {
ACTTAAAGTATAATAAGACGTGAGGTTTCGAAATCGATAAGCTTGGATCCAGCATGATAAGATACATTGATGA
GTTTGGACAAACCACAACAGTAGAATGCAGTGAATAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTG
TAACATTATAAGCTTCAATAAACAAGTTAACAACAACAATTGCATTATTTATGTTTCAGGTTCCAGGGGGAGGT
1st round primer for PolyA-seq
2nd round primer for PolyA-seq
GCAATAAACAAGTTAACAACAATAAAAAA (7A)
    
```

**c**




**d**

Genome-wide total L1-ORFeus insertion junctions




**e**




**f**

PolyA-seq (MYC sgRNA)




## Supplementary Figure 4 Continued



**Supplementary Figure 4. Development of PolyA-seq to capture genome-wide *de novo* L1-ORFeus insertion events.** **a**, Schematic representation of PolyA-seq by one-sided, nested amplification approach. The two-round forward primers were designed at the end of L1 GFP cassette (**a**, top), thus enable us to map the L1 retrotransposition sites genome-wide with the help of reverse linker primer (**a**, bottom). **b**, Detailed view of primers designed for PolyA-seq. PolyA-seq originates from SV40 PolyA and imposes a requirement for L1 insertions to have a minimal 15 bp Poly(A) tail (7A are imposed to primer directly and 8A are added during the sequence analysis). **c**, Numbers of total L1-ORFeus insertions mapped to the human genome obtained by PolyA-seq in HEK293T cells targeted by *MYC* CRISPR/Cas9 (**c**, left) or *RAG1* CRISPR/Cas9 (**c**, right) expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. Example sequences of PolyA-seq from *MYC* CRISPR editing in HEK293T cells expressing L1-ORFeus are shown in **Supplementary Sequence 11**. **d**, Sequence logo representing the consensus motif detected at L1 pre-integration sites obtained by PolyA-seq in HEK293T cells targeted by *MYC* CRISPR/Cas9 (**d**, left) or *RAG1* CRISPR/Cas9 (**d**, right) expressing L1-ORFeus. **e**, Distribution of 3' Poly(A) tract lengths of L1 insertions obtained by PolyA-seq in HEK293T cells expressing L1-ORFeus and targeted by *RAG1* CRISPR/Cas9. **f**, Sequence logo of L1 EN consensus motif surrounding *MYC* CRISPR/Cas9 target site obtained by PolyA-seq in HEK293T cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus. **g**, Detailed view of the distribution of L1-ORFeus insertions at the *RAG1* locus obtained by PolyA-seq in HEK293T cells targeted by *RAG1* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control (**g**, top). Corresponding GRO-seq, ChIP-seq (including Pol II, H3K4me3 and H3K27ac) and ATAC-seq profiles are shown (**g**, bottom). **h**, Sequence logo representing the consensus motif in example regions proximal or distant to the *RAG1* CRISPR/Cas9 DSB.




## Supplementary Figure 5







**Supplementary Figure 5. RT-dependent *de novo* L1-ORFeus insertions at CRISPR/Cas9 off-target sites in HEK293T cells.** **a**, Pie charts show the relative abundance of indicated three main types of insertions (i.e., L1-ORFeus, lentiCRISPR v2 plasmid and genomic fragments) obtained by amplicon sequencing at the MYC OT1 locus in HEK293T cells targeted by *MYC* CRISPR/Cas9 expressing GFP control or L1-ENm. **b**, Numbers of insertions mapped to the human genome (**b**, left) or lentiCRISPR v2 plasmid (**b**, right) obtained by amplicon sequencing at the MYC OT1 locus in HEK293T cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. **c,d**, Numbers and fragment lengths of L1-ORFeus insertions (**c**) or lentiCRISPR v2 plasmid insertions (**d**) obtained by amplicon sequencing at the MYC OT1 locus in HEK293T cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. The orientation of insertions is shown in orange when the fragment is oriented 5' to 3' (+) or blue when 3' to 5' (-).

# Supplementary Figure 6




# Supplementary Figure 6 Continued




**Supplementary Figure 6. Detailed characterization of *de novo* L1-ORFeus insertions at CRISPR/Cas9 target site in HeLa cells.** **a,b**, Percentage of GFP-positive HeLa cells at day 11 after L1-ORFeus transfection and introducing CRISPR/Cas9-mediated DSBs at the *MYC* locus (**a**) (Data are Mean $\pm$ SD, n=3 independent experiments); Intron assay was then performed to probe the L1-ORFeus retrotransposition events by genomic DNA-PCR (**b**). **c**, Editing efficiency of CRISPR/Cas9 at the *MYC* target site in HeLa cells expressing L1-ORFeus or L1-RTm. Data are Mean $\pm$ SD, n=6 independent experiments. **d**, Numbers of insertions mapped to LINE-1 (ORFeus) (**d**, left), lentiCRISPR v2 plasmid (**d**, middle) or the human genome (**d**, right) obtained by amplicon sequencing at the *MYC* locus in HeLa cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. **e-g**, Numbers and fragment lengths of L1-ORFeus insertions (**e**), lentiCRISPR v2 plasmid insertions (**f**) or chromosome 8 genomic insertions (**g**) obtained by amplicon sequencing at the *MYC* locus in HeLa cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. Example L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the *MYC* CRISPR/Cas9 target site in HeLa cells expressing L1-ORFeus are shown in **Supplementary Sequence 9**. **h**, L1-ORFeus junction analysis obtained by amplicon sequencing at the *MYC* locus targeted by *MYC* CRISPR/Cas9 in HeLa cells expressing L1-ORFeus. The sequence alignment was centered on the left end of CRISPR-Cas9-mediated DSBs. Other sources include genomic fragments or plasmid insertions. **i**, Histogram plots of microhomology lengths in junctions (data from **h**) joining L1-ORFeus to the left or right end of the CRISPR/Cas9-mediated DSB in HeLa cells expressing L1-ORFeus. **j**, Numbers of total L1-ORFeus insertions mapped to the human genome obtained by PolyA-seq in HeLa cells targeted by *MYC* CRISPR/Cas9 expressing L1-ORFeus or L1-RTm. **k**, Distribution of 3' Poly(A) tract lengths of L1-ORFeus insertions obtained by PolyA-seq in HeLa cells expressing L1-ORFeus and targeted by *MYC* CRISPR/Cas9. Source data are provided as a Source Data file.

## Supplementary Figure 7










**Supplementary Figure 7. RT-dependent *de novo* L1-ORFeus insertions at CRISPR/Cas9 target site in U2OS cells.** **a**, Percentage of GFP-positive U2OS cells at day 11 after L1-ORFeus transfection and CRISPR/Cas9-mediated DSBs at the *MYC* locus. Data are Mean $\pm$ SD, n=3 independent experiments. **b**, Intron assay was then performed. **c**, Editing efficiency of CRISPR/Cas9 at the *MYC* target site in U2OS cells expressing L1-ORFeus or L1-RTm. Data are Mean $\pm$ SD, n=3 independent experiments. **d**, Total L1-ORFeus insertions mapped to the human genome obtained by PolyA-seq in U2OS cells targeted by *MYC* CRISPR/Cas9 and expressing L1-ORFeus or L1-RTm. **e**, Distribution of 3' Poly(A) tract lengths of L1-ORFeus insertions obtained by PolyA-seq in U2OS cells targeted by *MYC* CRISPR/Cas9 and expressing L1-ORFeus. **f**, Numbers of L1-ORFeus insertions at the *MYC* locus obtained by PolyA-seq targeted by *MYC* CRISPR/Cas9 in U2OS cells that express L1-ORFeus or L1-RTm. **g**, Detailed view of the distribution of L1-ORFeus insertions at the *MYC* locus obtained by PolyA-seq in U2OS cells targeted by *MYC* CRISPR/Cas9 and expressing L1-ORFeus or L1-RTm. **h**, Sequence logos representing the consensus motif detected at L1-ORFeus pre-integration sites in indicated regions proximal or distant to the *MYC* CRISPR/Cas9 DSB in chromosome 8. The canonical consensus motif in chromosome 1 served as a control. Source data are provided as a Source Data file.

## Supplementary Figure 8




**Supplementary Figure 8. RT-dependent *de novo* L1RP insertions at CRISPR/Cas9 target site in HEK293T cells.** **a**, Schematic representation of pCEP4 GFP control, pCEP4 L1RP, pCEP4 L1RP-ENm (H230A) (L1RP-ENm), and pCEP4 L1RP-RTm (D702Y) (L1RP-RTm) plasmids. **b**, Schematic of the experimental strategy employed to examine *de novo* L1RP retrotransposition events at the *MYC* CRISPR/Cas9 target site in HEK293T cells. PolyA-seq is performed on the bulk population of cells without GFP sorting. **c**, HEK293T cells were transfected with 1  $\mu$ g L1RP reporters or L1-ORFeus reporter, and Western Blot was performed to detect L1 ORF1p protein;  $\beta$ -actin expression served as loading control. **d**, Editing efficiency of CRISPR/Cas9 at the *MYC* target site in HEK293T cells expressing L1RP or L1RP-RTm. Data are Mean $\pm$ SD, n=4 independent experiments. **e**, Distribution of 3' Poly(A) tract lengths of L1RP insertions obtained by PolyA-seq in HEK293T cells expressing L1RP and targeted by *MYC* CRISPR/Cas9. **f**, Numbers of total L1RP insertions mapped to the human genome obtained by PolyA-seq in HEK293T cells targeted by *MYC* CRISPR/Cas9 and expressing L1RP, L1RP-ENm, L1RP-RTm or GFP control. Source data are provided as a Source Data file.

# Supplementary Figure 9




# Supplementary Figure 9 Continued






**Supplementary Figure 9. Safety evaluation of prime editing at the *MYC* (+2-4AAA del) site in HEK293T cells.** **a**, Similar to **Fig. 1b**, schematic of the experimental strategy employed to examine *de novo* L1-ORFeus retrotransposition events at the *MYC* prime editing site in HEK293T cells. **b,c**, Percentage of GFP-positive HEK293T cells at day 11 after L1-ORFeus transfection and introducing PE2 (*MYC* +2-4AAA del), PE3 (*MYC* +2-4AAA del) or nick only for PE3 (**b**) (Data are Mean±SD, n=3 independent experiments), Intron assay was then performed to probe the L1-ORFeus retrotransposition events by genomic DNA-PCR (**c**). **d**, Prime editing efficiency of PE2 (*MYC* +2-4AAA del), PE3 (*MYC* +2-4AAA del) or nick only for PE3 at the *MYC* locus in HEK293T cells expressing L1-ORFeus or L1-RTm. Data are Mean±SD, n=3 independent experiments. **e**, Numbers of insertions mapped to pCMV-PE2 plasmid (**e**, top), the human genome (**e**, middle) or pU6-pegRNA (**e**, bottom) obtained by amplicon sequencing at the *MYC* locus in HEK293T cells targeted by PE2 (*MYC* +2-4AAA del), PE3 (*MYC* +2-4AAA del) or nick only for PE3 expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. **f-i**, Numbers and fragment lengths of L1-ORFeus insertions (**f**), pCMV-PE2 plasmid insertions (**g**), pU6-pegRNA insertions (**h**) or chromosome 8 insertions (**i**) obtained by amplicon sequencing at the *MYC* locus in HEK293T cells targeted by PE3 (*MYC* +2-4AAA del) expressing L1-ORFeus, L1-ENm, L1-RTm or GFP control. The orientation of insertions is shown in orange when the fragment is oriented 5' to 3' (+) or blue when 3' to 5' (-). Source data are provided as a Source Data file.

# Supplementary Figure 10




**Supplementary Figure 10. Safety evaluation of prime editing at the *MYC* (+5GtoC) or *FANCF* (+5GtoT) site in HEK293T cells.** **a**, Percentage of GFP-positive HEK293T cells at day 11 after L1-ORFeus transfection and introducing PE2 (*MYC* +5GtoC), PE3 (*MYC* +5GtoC), PE3b (*MYC* +5GtoC) or nick only for PE3/PE3b (**a**, top). Data are Mean±SD, n=3 independent experiments. Intron assay was performed to probe the L1-ORFeus retrotransposition events by genomic DNA-PCR at day 11 (**a**, bottom). **b**, Percentage of GFP-positive HEK293T cells at day 11 after L1-ORFeus transfection and introducing PE2 (*FANCF* +5GtoT), PE3 (*FANCF* +5GtoT), PE3b (*FANCF* +5GtoT) or nick only for PE3/PE3b (**b**, top). Data are Mean±SD, n=3 independent experiments. Intron assay was then performed (**b**, bottom). **c,d**, Precise prime editing efficiency of the indicated prime editors at the *MYC* +5GtoC (**c**) or *FANCF* +5GtoT (**d**) site in HEK293T cells expressing L1-ORFeus or L1-RTm. Data are Mean±SD, n=3 independent experiments. **e,f**, Numbers of insertions mapped to LINE-1 (ORFeus), pCMV-PE2 plasmid, the human genome or pU6-pegRNA in HEK293T cells expressing L1-ORFeus or L1-RTm. Amplicon sequencing was analyzed at the *MYC* locus targeted by PE2 (*MYC* +5GtoC), PE3 (*MYC* +5GtoC), PE3b (*MYC* +5GtoC) or nick only for PE3/PE3b (**e**) or at the *FANCF* locus targeted by PE2 (*FANCF* +5GtoT), PE3 (*FANCF* +5GtoT), PE3b (*FANCF* +5GtoT) or nick only for PE3/PE3b (**f**). Source data are provided as a Source Data file.

# Supplementary Figure 11




Supplementary Figure 11 to be continued

## Supplementary Figure 11 Continued




**Supplementary Figure 11. Characterization of PE3 (*MYC* +5GtoC) and PE3 (*FANCF* +5GtoT) editing in HEK293T cells. a,b**, Pie charts show the relative abundance of four main types of insertions (i.e., L1-ORFeus, pCMV-PE2 plasmid, pU6-pegRNA or genomic fragments) obtained by amplicon sequencing at the *MYC* locus targeted by PE3 (*MYC* +5GtoC) (a) or at the *FANCF* locus targeted by PE3 (*FANCF* +5GtoT) (b) in HEK293T cells expressing L1-ORFeus or L1-RTm. c-h, Numbers and fragment lengths of L1-ORFeus insertions (c,d), pCMV-PE2 plasmid insertions (e,f) or pU6-pegRNA insertions (g,h) obtained by amplicon sequencing at the *MYC* locus targeted by PE3 (*MYC* +5GtoC) (c,e,g) or PE3 (*FANCF* +5GtoT) (d,f,h) in HEK293T cells expressing L1-ORFeus or L1-RTm. The orientation of insertions is shown in orange when the fragment is oriented 5' to 3' (+) or blue when 3' to 5' (-).

# Supplementary Figure 12




## Supplementary Figure 12 Continued




**Supplementary Figure 12. Characterization of *de novo* L1-ORFeus insertions in PE3 edited HEK293T cells.** **a-c**, Prime editing efficiency in sequences with four indicated types of insertions compared to the bulk sequences. Amplicon sequencing was analyzed in HEK293T cells expressing L1-ORFeus at the *MYC* locus targeted by PE3 (*MYC* +2-4AAA del) (**a**) or PE3 (*MYC* +5GtoC) (**b**), or at the *FANCF* locus targeted by PE3 (*FANCF* +5GtoT) (**c**). Data are Mean $\pm$ SD, n=3 independent experiments. \* p < 0.05, \*\* p < 0.005, \*\*\* p < 0.0005. **d**, Prime editing efficiency was independent of the L1-ORFeus insertion orientation. **e-g**, L1-ORFeus junction analysis obtained by amplicon sequencing at the *MYC* locus targeted by PE3 (*MYC* +2-4AAA del) (**e**) or PE3 (*MYC* +5GtoC) (**f**), or at the *FANCF* locus targeted by PE3 (*FANCF* +5GtoT) (**g**) in HEK293T cells expressing L1-ORFeus. The sequence alignment was centered on the pegRNA-mediated nick site. Other sources include genomic fragments or plasmid insertions. Edited sequences: sequences containing the pegRNA-edited site; non-edited sequences: sequences containing wild type *MYC*; sequences with deletion of the editing site: sequences in which the editing site was deleted during L1-ORFeus insertion. **h**, Histogram plots of microhomology lengths in junctions (pooled from **e-g**) joining L1-ORFeus to pegRNA-mediated nicking site (on the edited strand) or sgRNA-mediated nicking site (on the non-edited strand) in HEK293T cells expressing L1-ORFeus. **i**, Numbers of total L1-ORFeus insertions mapped to the human genome obtained by PolyA-seq in cells targeted by PE3 (*MYC* +2-4AAA del), PE3 (*MYC* +5GtoC) or PE3b (*MYC* +5GtoC) expressing L1-ORFeus or L1-RTm. Source data are provided as a Source Data file.

# Supplementary Figure 13








## Supplementary Figure 13 Continued



**Supplementary Figure 13. *De novo* L1-ORFeus insertions are rare in base editing in HEK293T cells.** **a,b**, Percentage of GFP-positive HEK293T cells at day 11 after L1-ORFeus transfection and introducing BE2, BE3, BE4-Gam, AncBE4max or ABE8e editing at the *MYC* (**a**, top) or *FANCF* locus (**b**, top). Data are Mean $\pm$ SD, n=3 independent experiments. Intron assay was then performed (**a,b**, bottom). **c**, GFP-positive HEK293T cells were analyzed after introducing ABE8e editing at the *BCL11A* enhancer or *HBG1/2* promoter (-198bp/-175bp target) sites (**c**, top), Intron assay was then performed (**c**, bottom). Data are Mean $\pm$ SD, n=3 independent experiments. **d,e**, Base editing efficiency at the *MYC* (**d**) or *FANCF* locus (**e**) in HEK293T cells expressing L1-ORFeus or L1-RTm. Data are Mean $\pm$ SD, n=3 independent experiments. **f**, ABE8e editing efficiency at the *BCL11A* enhancer or *HBG1/2* promoter sites in HEK293T cells expressing L1-ORFeus or L1-RTm. Data are Mean $\pm$ SD, n=3 independent experiments. **g,h**, Numbers of insertions mapped to indicated pCMV-BE plasmid or the human genome obtained by amplicon sequencing at the *MYC* (**g**) or *FANCF* (**h**) base editing site in HEK293T cells targeted by BE2, BE3, BE4-Gam, AncBE4max or ABE8e expressing L1-ORFeus or L1-RTm. **i**, Numbers of insertions mapped to pCMV-ABE8e plasmid or the human genome obtained by amplicon sequencing at the *BCL11A* enhancer or *HBG1/2* promoter editing sites in HEK293T cells targeted by ABE8e expressing L1-ORFeus or L1-RTm. **j**, Numbers of total L1-ORFeus insertions obtained by PolyA-seq in HEK293T cells targeted by AncBE4max or ABE8e at the *MYC* base editing site expressing L1-ORFeus or L1-RTm. **k**, Numbers of total L1-ORFeus insertions obtained by PolyA-seq in HEK293T cells targeted by ABE8e at the *BCL11A* enhancer or *HBG1/2* promoter sites expressing L1-ORFeus or L1-RTm. **l,m**, GRO-seq, ChIP-seq and ATAC-seq profiles are shown at the *FANCF* (**l**) or *BCL11A* enhancer (**m**) base editing site. **n**, Detailed view of the distribution of L1-ORFeus insertions at the *HBG1/2* promoter base editing sites obtained by PolyA-seq in HEK293T cells targeted by ABE8e expressing L1-ORFeus or L1-RTm (**n**, top). GRO-seq, ChIP-seq and ATAC-seq profiles are shown (**n**, bottom). Source data are provided as a Source Data file.

# Supplementary Figure 14



**Supplementary Figure 14. Endogenous L1 sequences found at CRISPR/Cas9 target sites in HEK293T cells.** **a,b**, Numbers of sequences mapped to the endogenous L1s sequences obtained by amplicon sequencing at the *MYC* locus targeted by *MYC* CRISPR/Cas9 (**a**) or at the *RAG1* locus targeted by *RAG1* CRISPR/Cas9 (**b**) in HEK293T cells. Two example L1 sequences are shown in **Supplementary Sequence 12**. **c**, Histogram showing numbers of L1s sequences found at *MYC* CRISPR/Cas9 target site (**c**, left) or *RAG1* CRISPR/Cas9 target site (**c**, right).

## Supplementary Tables

**Supplementary Table 1.** Sequences of sgRNAs, pegRNAs and nicking sgRNAs (for PE3 or PE3b) used for mammalian cell experiments. All sequences are shown in 5' to 3' orientation.

**Supplementary Table 2.** Sequences of CRISPR off-targets (OT).

**Supplementary Table 3.** Primers for RT-PCR and Intron assay.

**Supplementary Table 4.** Primers for amplicon sequencing.

**Supplementary Table 5.** Primers for PolyA-seq.

**Supplementary Table 1.** Sequences of sgRNAs, pegRNAs, nicking sgRNAs (for PE3 or PE3b) and primers for amplifying target locus. All sequences are shown in 5' to 3' orientation.

### 1.1 sgRNAs in lentiCRISPR v2 vector (for canonical CRISPR/Cas9 genome editing)

| Locus | Spacer sequence (PAM)   | Chromosome (strand) | Start       | End         |
|-------|-------------------------|---------------------|-------------|-------------|
| MYC   | GACTGTCCAAAGGGGGTCAAAGG | chr8 (+)            | 127,738,062 | 127,738,081 |
| RAG1  | GCCTCTTCCCACCCACCTGGG   | chr11 (+)           | 36,573,311  | 36,573,330  |
| CCR5  | CAGAATTGATACTGACTGTATGG | chr3 (-)            | 46,373,452  | 46,373,471  |

### 1.2 sgRNAs in pU6-sgRNA vector (for Base Editors)

| Locus                       | Spacer sequence (PAM)   | Chromosome (strand) | Start                  | End                    |
|-----------------------------|-------------------------|---------------------|------------------------|------------------------|
| MYC                         | GACTGTCCAAAGGGGGTCAAAGG | chr8 (+)            | 127,738,062            | 127,738,081            |
| FANCF                       | GGAATCCCTTCTGCAGCACCTGG | chr11 (-)           | 22,625,789             | 22,625,808             |
| BCL11A enhancer             | TTTATCACAGGCTCCAGGAAAGG | chr2 (-)            | 60,495,252             | 60,495,271             |
| HBG1/2 promoter -198 target | GTGGGGAAGGGGCCCAAGAGG   | chr11 (+)           | 5,250,049*             | 5,250,068*             |
|                             |                         |                     | 5,254,973 <sup>#</sup> | 5,254,992 <sup>#</sup> |
| HBG1/2 promoter -175 target | ATATTGCATTGAGATAGTGG    | chr11 (+)           | 5,250,030*             | 5,250,049*             |
|                             |                         |                     | 5,254,954 <sup>#</sup> | 5,254,973 <sup>#</sup> |

\*HBG1 promoter <sup>#</sup>HBG2 promoter

### 1.3 pegRNAs in pU6-pegRNA vector (for Prime Editors)

| pegRNA          | Spacer sequence (PAM)   | 3' extension                     | PBS length (nt) | RT template length (nt) |
|-----------------|-------------------------|----------------------------------|-----------------|-------------------------|
| MYC +2-4AAA del | GACTGTCCAAAGGGGGTCAAAGG | ATAAAGGGAGCACCCACCCCTTTGGAC      | 13              | 16                      |
| MYC +5GtoC      | GACTGTCCAAAGGGGGTCAAAGG | AGGGAGCACCGTTTCACCCCTTTGGAC      | 13              | 15                      |
| FANCF +5GtoT    | GGAATCCCTTCTGCAGCACCTGG | GGAAAAGCGATCAAGGTGCTGCAGAAGGGATT | 15              | 17                      |

Mutated bases are listed in red

### 1.4 Nicking sgRNAs in pU6-pegRNA vector (for Prime Editors)

| Nicking sgRNA | Purpose                                       | Spacer sequence (PAM)   |
|---------------|---|-------------------------|
| MYC +42       | For PE3 (both MYC +2-4AAA del and MYC +5GtoC) | GAGCTATCCCCTAAAGCGGCTGG |
| MYC -5        | For PE3b (MYC +5GtoC)                         | GAGCACCGTTTCACCCCTTTGG  |
| FANCF +48     | For PE3                                       | GGGTCCCAGGTGCTGACGTAGG  |
| FANCF +7      | For PE3b                                      | GAAGCTCGAAAAGCGATCAAGG  |

Mutated bases are listed in red

### 1.5 Primers for amplifying target locus (for surveyor assay and/or sanger sequencing)

| Locus           | Forward primer             | Reverse primer           | PCR product length (bp) | Annealing temperature (°C) |
|-----------------|----------------------------|--------------------------|-------------------------|----------------------------|
| MYC             | ACTTTGTGCCTTGGATTTGG       | GCAGCAGCTCGAATTTCTTCCA   | 568                     | 58                         |
| RAG1            | GTAACCATAAACACTGTCAGAAGAGG | AGGACTGCTGGAGATTGCTC     | 407                     | 57                         |
| CCR5            | GGCTCTATTTTATAGGCTTCTCTCT  | TGGTCCAACCTGTTAGAGCTACTG | 514                     | 58                         |
| FANCF           | GTAGGATGCCCTACATCTGCT      | GTTCTGTAATCCCGGAAGTGG    | 488                     | 58                         |
| BCL11A enhancer | CTATGCCCCAGGTGTGCATAAG     | CCATCACCAAGAGAGCCTTCCGA  | 301                     | 59                         |
| HBG1/2 promoter | TGATAACCTCAGACGTTCCAG      | CTGACAAAAGAAGTCTGGTATC   | 378* / 374 <sup>#</sup> | 56                         |


\*HBG1 promoter <sup>#</sup>HBG2 promoter

**Supplementary Table 2.** Sequences of CRISPR off-targets (OT).

| CRISPR target | CRISPR off-targets | Associated Gene | Spacer sequence (PAM)   | Mismatch /Gap | Chromosome (strand) | Start       | End         |
|---------------|--------------------|-----------------|-------------------------|---------------|---------------------|-------------|-------------|
| MYC           | On-target          | MYC             | GACTGTCCAAGGGGGTAAAGG   | 0             | chr8 (+)            | 127,738,062 | 127,738,081 |
|               | MYC OT1            |                 | GAACTGTCCAAGGGGGTGA-AGG | 2             | chrX (-)            | 153,624,558 | 153,624,577 |
|               | MYC OT2            | MYO15A          | CCCTGCCCAAGGGGGTGAACGG  | 4             | chr17 (+)           | 18,122,096  | 18,122,115  |
| RAG1          | On-target          | RAG1            | GCCTCTTCCACCCACCTTGGG   | 0             | chr11 (+)           | 36,573,311  | 36,573,330  |
|               | RAG1 OT1           | DAZAP1          | ACCCCTTCCCACCTACCTTGGG  | 4             | chr19 (-)           | 1,417,538   | 1,417,557   |
|               | RAG1 OT2           |                 | TCCTCCTCCCACCCACCTCAG   | 4             | chr12 (-)           | 46,609,202  | 46,609,221  |
|               | RAG1 OT3           | SIN3A           | TCCTCTCACCACCCACCTCCGG  | 3             | chr15 (-)           | 75,454,316  | 75,454,335  |

Mismatches/Gaps are listed in red

**Supplementary Table 3.** Primers for RT-PCR and Intron assay.



| Purpose | Locus       | Forward primer         | Reverse primer         | PCR product length (bp) | Annealing temperature (°C) |
|---------|-------------|------------------------|------------------------|-------------------------|----------------------------|
| RT-PCR  | <i>ORF1</i> | GAGAACGACTTCGACGAGCTG  | ACTTCTCGGTGTTGGTGATG   | 151                     | 57                         |
|         | <i>ORF2</i> | CAAGAGCTGCTGCTACAAGGAC | CAGGTGCCACGAAGCTGATG   | 189                     | 57                         |
|         | <i>HPRT</i> | CTGGCGTCGTGATTAGTGATG  | GAGCACACAGAGGGCTACAATG | 188                     | 57                         |

| Purpose      | Locus      | Forward primer        | Reverse primer        | PCR product length (bp)  | Annealing temperature (°C) |
|--------------|------------|-----------------------|-----------------------|--------------------------|----------------------------|
| Intron assay | <i>GFP</i> | ACGAACTCCAGCAGGACCATG | GCATCGACTTCAAGGAGGACG | 1192* / 292 <sup>#</sup> | 59                         |

\*with intron    #without intron

**Supplementary Table 4. Primers for amplicon sequencing.**

**4.1 Forward primers for amplicon sequencing for MYC locus**

| Primer name | sequence  |
|-------------|---|
| MYC-F Mi0   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGCTGGTTCCTAAGTGCCT            |
| MYC-F Mi1   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTAAGTAGAGGCTGGTTCCTAAGTGCCT   |
| MYC-F Mi2   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGCTGGTTCCTAAGTGCCT          |
| MYC-F Mi3   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATACACGATCGCTGGTTCCTAAGTGCCT  |
| MYC-F Mi4   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCTGCTGGTTCCTAAGTGCCT        |
| MYC-F Mi5   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGATCGCGCGGTGCTGGTTCCTAAGTGCCT |
| MYC-F Mi6   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGATACGCTGGTTCCTAAGTGCCT      |
| MYC-F Mi7   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATCATGATCGCTGGTTCCTAAGTGCCT |
| MYC-F Mi8   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGACTTGCTGGTTCCTAAGTGCCT      |
| MYC-F Mi9   | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGATCGTTACCACTGGTTCCTAAGTGCCT |
| MYC-F Mi10  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTAACAATGGCTGGTTCCTAAGTGCCT    |
| MYC-F Mi11  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATACTGATCGCTGGTTCCTAAGTGCCT   |
| MYC-F Mi12  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCCTGCTGGTTCCTAAGTGCCT     |
| MYC-F Mi13  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCGAGGCATGCTGGTTCCTAAGTGCCT  |
| MYC-F Mi14  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTCCGCTGCTGGTTCCTAAGTGCCT    |
| MYC-F Mi15  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTACGACGCTGGTTCCTAAGTGCCT     |

Illumina Miseq adaptor (Forward sequence) Barcode MYC-F

**Reverse primers for amplicon sequencing for MYC locus**

| Primer name | sequence  |
|-------------|---|
| MYC-R Mi0   | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCTCTCCCCTTGCAGAGCTATCC       |
| MYC-R Mi1   | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGAGCTCTCCCCTTGCAGAGCTATCC    |
| MYC-R Mi2   | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTGAGAGCTCTCCCCTTGCAGAGCTATCC |
| MYC-R Mi3   | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTACGTGAATCTCCCCTTGCAGAGCTATCC |
| MYC-R M4    | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGCTACTCTCCCCTTGCAGAGCTATCC   |

Illumina Miseq adaptor (Reverse sequence) Barcode MYC-R

**4.2 Forward primers for amplicon sequencing for RAG1 locus**

| Primer name | sequence  |
|-------------|---|
| RAG1-F Mi0  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTAAGATACATCAGTGGGATATTG           |
| RAG1-F Mi1  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACGGCTGGTAAAGATACATCAGTGGGATATTG  |
| RAG1-F Mi2  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGTATGCTAAAGATACATCAGTGGGATATTG   |
| RAG1-F Mi3  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTCAAAGATACATCAGTGGGATATTG        |
| RAG1-F Mi4  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGATTAAGATACATCAGTGGGATATTG        |
| RAG1-F Mi5  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATCACTGCGTAAAGATACATCAGTGGGATATTG |

Illumina Miseq adaptor (Forward sequence) Barcode RAG1-F

**Reverse primers for amplicon sequencing for RAG1 locus**

| Primer name | sequence   |
|-------------|--|
| RAG1-R Mi0  | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTAGGATCTCACCCGGAACAGC        |
| RAG1-R Mi1  | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTCAGAGGATCTCACCCGGAACAGC    |
| RAG1-R Mi2  | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGATCGACAGGATCTCACCCGGAACAGC |

Illumina Miseq adaptor (Reverse sequence) Barcode RAG1-R

**4.3 Forward primers for amplicon sequencing for CCR5 locus**

| Primer name | sequence   |
|-------------|--|
| CCR5-F Mi0  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCCAGGAATCATCTTTACCAGATCT         |
| CCR5-F Mi1  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATGATGTACCAGGAATCATCTTTACCAGATCT |
| CCR5-F Mi2  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCTATCCAGGAATCATCTTTACCAGATCT   |
| CCR5-F Mi3  | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGATCCAGGAATCATCTTTACCAGATCT      |

Illumina Miseq adaptor (Forward sequence) Barcode CCR5-F

**Reverse primers for amplicon sequencing for CCR5 locus**

| Primer name | sequence   |
|-------------|--|
| CCR5-R Mi0  | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCAGGACCAGCCCCAAGATGACTA     |
| CCR5-R Mi1  | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTGCTCAGGACCAGCCCCAAGATGACTA |

Illumina Miseq adaptor (Reverse sequence) Barcode CCR5-R



#### 4.4 Forward primers for amplicon sequencing for MYC off-targets #1 (MYC OT1) locus

| Primer name   | sequence   |
|---------------|--|
| MYC OT1-F Mi0 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCCTTACTTGAAGCCAGAGGTC          |
| MYC OT1-F Mi1 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTAGCTCCTTACTTGAAGCCAGAGGTC    |
| MYC OT1-F Mi2 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTAGCTAGACCCTTACTTGAAGCCAGAGGTC |
| MYC OT1-F Mi3 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCAGCCTTACTTGAAGCCAGAGGTC     |

Illumina Miseq adaptor (Forward sequence) Barcode MYC OT1-F

#### Reverse primers for amplicon sequencing for MYC off-targets #1 (MYC OT1) locus

| Primer name   | sequence  |
|---------------|---|
| MYC OT1-R Mi0 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCACAGGACCGTGCCTCCTAGC        |
| MYC OT1-R Mi1 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTGACATGCACAGGACCGTGCCTCCTAGC |
| MYC OT1-R Mi2 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGCTGCACAGGACCGTGCCTCCTAGC    |

Illumina Miseq adaptor (Reverse sequence) Barcode MYC OT1-R

#### 4.5 Forward primers for amplicon sequencing for FANCF locus

| Primer name | sequence   |
|-------------|--|
| FANCF-F Mi0 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGAGTCGCCGTCTCCAAGGTG          |
| FANCF-F Mi1 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTACGTCACCTAGAGTCGCCGTCTCCAAGGTG |
| FANCF-F Mi2 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTCAGTACAGAGTCGCCGTCTCCAAGGTG  |
| FANCF-F Mi3 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGCAGAGTCGCCGTCTCCAAGGTG        |
| FANCF-F Mi4 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCAAGAGTCGCCGTCTCCAAGGTG     |
| FANCF-F Mi5 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCACAGCAGAGTCGCCGTCTCCAAGGTG    |

Illumina Miseq adaptor (Forward sequence) Barcode FANCF-F

#### Reverse primers for amplicon sequencing for FANCF locus

| Primer name | sequence   |
|-------------|--|
| FANCF-R Mi0 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGATGGATGTGGCGCAGGTAG          |
| FANCF-R Mi1 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTACGACGCGCGATGGATGTGGCGCAGGTAG |
| FANCF-R Mi2 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCGCATGCAGATGGATGTGGCGCAGGTAG  |
| FANCF-R Mi3 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGTCGATGGATGTGGCGCAGGTAG       |
| FANCF-R Mi4 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTGATGATGGATGTGGCGCAGGTAG      |
| FANCF-R Mi5 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCATACGATGGATGTGGCGCAGGTAG     |

Illumina Miseq adaptor (Reverse sequence) Barcode FANCF-R

#### 4.6 Forward primers for amplicon sequencing for BCL11A enhancer locus

| Primer name  | sequence  |
|--------------|---|
| BCL11A-F Mi0 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCTTACAGATAACACACCAGG      |
| BCL11A-F Mi1 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCAGCTCTTACAGATAACACACCAGG |

Illumina Miseq adaptor (Forward sequence) Barcode BCL11A-F

#### Reverse primers for amplicon sequencing for BCL11A enhancer locus

| Primer name  | sequence   |
|--------------|--|
| BCL11A-R Mi0 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTAGAGGCTGCCAGTCCCTCTTC     |
| BCL11A-R Mi1 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTACTCAGAGGCTGCCAGTCCCTCTTC |
| BCL11A-R Mi2 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTCTGCAGAGGCTGCCAGTCCCTCTTC |

Illumina Miseq adaptor (Reverse sequence) Barcode BCL11A-R

#### 4.7 Forward primers for amplicon sequencing for HBG1/2 promoter locus

| Primer name  | sequence   |
|--------------|--|
| HBG1/2-F Mi0 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTGCCTTGTCAAGGCTATTGGTC       |
| HBG1/2-F Mi1 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTATGACGTGCCTTGTCAAGGCTATTGGTC |

Illumina Miseq adaptor (Forward sequence) Barcode HBG1/2-F

#### Reverse primers for amplicon sequencing for HBG1/2 promoter locus

| Primer name  | sequence   |
|--------------|--|
| HBG1/2-R Mi0 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTTGAATGACTGAATCGGAAC       |
| HBG1/2-R Mi1 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTACTGCTGGAATGACTGAATCGGAAC |
| HBG1/2-R Mi2 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTTCCGATCTGACTGGAATGACTGAATCGGAAC   |

Illumina Miseq adaptor (Reverse sequence) Barcode HBG1/2-R

## Supplementary Table 5. Primers for PolyA-seq.

### 5.1 PolyA-seq primers

| Primer name      | Sequences  |
|------------------|--|
| Biotin-LEAP      | /5biosg/GTTTCGAAATCGATAAGCTTGGATCC (1st round primer for PolyA-seq)                        |
| SV40-polyA-F     | GCAATAAACAAAGTTAACACAAAAAAAAA (2nd round primer for PolyA-seq)                             |
| SV40-polyA-F Mi0 | AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTCCGATCTGCAATAAACAAAGTTAACACAAAAAAAAA      |
| SV40-polyA-F Mi1 | AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTCCGATCTATGCAATAAACAAAGTTAACACAAAAAAAAA    |
| SV40-polyA-F Mi2 | AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTCCGATCTTGCAGCAATAAACAAAGTTAACACAAAAAAAAA  |
| SV40-polyA-F Mi3 | AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTCCGATCTCAGTGCAATAAACAAAGTTAACACAAAAAAAAA  |
| SV40-polyA-F Mi4 | AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTCCGATCTACTACGCAATAAACAAAGTTAACACAAAAAAAAA |

Illumina Miseq adaptor (Forward sequence) Barcode SV40-polyA-F

### 5.2 Linker sequence

| Name                | Sequence  | Purpose                            |
|---------------------|---|------------------------------------|
| HaeIII upper linker | GTAATACGACTCACTATAGGGCACGCGTGGTTCGACGGCCGGGCTGGTTAT | The upper strand of ligated linker |
| HaeIII lower linker | TAACCAGCCC (5'P, 3'inverted dT)                     | The lower strand of ligated linker |
| AP1                 | GTAATACGACTCACTATAGGGC                              | 1st round linker primer            |
| AP2                 | ACTATAGGGCACGCGTGGTC                                | 2nd round linker primer            |

### 5.3 Reverse barcoding primers for Illumina Miseq sequencing

| Primer name | Sequence  |
|-------------|---|
| AP2-PE7 Mi0 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTACTATAGGGCACGCGTGGT             |
| AP2-PE7 Mi1 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTTCCGATCTGCGTACTATAGGGCACGCGTGGT |
| AP2-PE7 Mi2 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTGAGTCGCTAGACTATAGGGCACGCGTGGT   |
| AP2-PE7 Mi3 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTCTACGCTACTATAGGGCACGCGTGGT      |
| AP2-PE7 Mi4 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTATGCACTATAGGGCACGCGTGGT         |
| AP2-PE7 Mi5 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTGCACTATAGGGCACGCGTGGT           |
| AP2-PE7 Mi6 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTTGCTGACTATAGGGCACGCGTGGT        |
| AP2-PE7 Mi7 | CAAGCAGAAGACGGCATAACGAGATCGGTCTCGGCATTCTGCTGAACCGCTCTCCGATCTCATACTATAGGGCACGCGTGGT          |

Illumina Miseq adaptor (Reverse sequence) Barcode AP2 sequence

## Supplementary Sequences

**Supplementary Sequence 1.** DNA sequences of pCEP4 GFP control, pCEP4 L1-ORFeus, pCEP4 L1-ORFeus-ENm (H230A) (L1-ENm), and pCEP4 L1-ORFeus-RTm (D702Y) (L1-RTm) plasmids used in this study.

**Supplementary Sequence 2.** DNA sequences of endogenous human L1 (L1Hs and L1RP)

**Supplementary Sequence 3.** DNA sequences of pU6-pegRNAs, lentiCRISPR v2 plasmid, pCMV-PE2 plasmid, pCMV-BEs (BE2/BE3/BE4-Gam/AncBE4max/ABE8e) plasmids used for insertion sources analysis.

**Supplementary Sequence 4.** Example L1-ORFeus insertional sequences obtained by amplicon sequencing at the PE3 (MYC +2-4AAA del) editing site in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 5.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the PE3 (MYC +2-4AAA del) editing site in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 6.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the MYC CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 7.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the RAG1 CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 8.** L1-ORFeus insertion bridging the intron of GFP obtained by amplicon sequencing at the CCR5 CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 9.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the MYC CRISPR/Cas9 target site in HeLa cells expressing L1-ORFeus.

**Supplementary Sequence 10.** L1-ORFeus insertional sequence obtained by amplicon sequencing at the CCR5 CRISPR/Cas9 target site in HEK293T cells expressing L1-RTm.


**Supplementary Sequence 11.** Example sequences of PolyA-seq from MYC CRISPR editing in HEK293T cells expressing L1-ORFeus.

**Supplementary Sequence 12.** Example L1Hs sequences obtained by amplicon sequencing at the MYC/RAG1 CRISPR/Cas9 target site in HEK293T cells.

**Supplementary Sequence 13.** DNA sequences of pCEP4 L1RP, pCEP4 L1RP-ENm (H230A) (L1RP-ENm), and pCEP4 L1RP-RTm (D702Y) (L1RP-RTm) plasmids used in this study.

**Supplementary Sequence 1.** DNA sequences of pCEP4 GFP control, pCEP4 L1-ORFeus, pCEP4 L1-ORFeus-ENm (H230A) (L1-ENm), and pCEP4 L1-ORFeus-RTm (D702Y) (L1-RTm) plasmids used in this study.

### 1.1 pCEP4 GFP control vector (1-10646bp)




| Features            | Regions (bp) |
|---------------------|--------------|
| CMV promoter        | 30-605       |
| EGFP                | 652-1368     |
| SV40 poly(A) signal | 1415-1549    |
| EBV-oriP            | 2278-4067    |
| EBNA1               | 4369-6294    |
| AmpR                | 6920-7780    |
| pUC origin          | 7951-8539    |
| PuroR               | 9273-9872    |

GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTCCCGGTTACATAACTTACCGT  
AAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC  
ATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCACTTGGCAGTACATCAAGTGATCATATGCCAAGTCCGCCCTATTGACGTCAA  
TGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT  
ACCATGGTGATCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTACTCACGGGGATTCCAAAGTCTCCACCCATTGACGTCAA  
TGGGAGTTTTGTTTGGCACAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCGTTGACGCAAATGGGCGGTAGGCGGTGAC  
GGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTAGTGAACCGTCAGATCTCTAGAAGCTGGGTACCAGCTGCTAGCGCTACCGGTCCGCCACC  
**ATGGTGAGCAAAGGGCAGGAGCTGTTTACCGGGGGTGGTCCCTATCGAGTTCGAGCTGACGGCGAGTCAAGCCGCAAGTTCAAGTTCAGGCTG**  
**TCCGCGGAGGGCGAGGGCGATGCCACTACGGCAAGCTGACCTGAAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCTGGCCCA**  
**CCCTCGTGACCACCTGACCTACGGCGTGCAGTGTTCAGCCGCTACCCGACCACATGAAGCAGCAGGACTTCTTCAAGTCCGCCATG**  
**CCGGAAGGCTACGTCCAGGAGCGACCATCTTCTTCAAGGACGAGGGCAACTACAAGACCCGCGGAGGTGAAGTTCGAGGGCGACA**  
**CCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCTGGGGCACAAGCTGGAGTACAACATAACAG**  
**CCACAACGTTCTATATCATGGCCGACAAGCAGAAGAAGCGCATCAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGC**  
**AGCTCGCCGACCCTACCGCAGACAACCCCTACGGCGACGGCCCGTGTCTGCCGACAACCACACTGAGCACCCGCGC**  
**CCTGAGCAAAGACCCCAACGAGAAGCGGATCACATGGTCTGCTGGAGTTCGTGACCGCCCGGGGATCACTCTCGGCATGGACGAG**  
**CTGTACAAGTCCGGACTCAGATCTCGAGCTCAAGCTTCGAATAGCGCCGCTAAGGATCCAGACATGATAAGATACATTGATGAGTTGGACA**  
AACCACAACATAAGTGCAGTGAATAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATATAAGTCAATAAACAAGTT  
AACAACAACAAATTGCATTCATTTTATGTTTCAGGTTACAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAATGTGGTATGG  
CTGATTATGATCCGGCTGCCTCGCGCTTTCCGGTATGACCGTGAACCTCTGACACATGCAGCTCCCGGAGACGGTACAGCTTGTCTG  
TAAGCGGATGCCGGGAGCAGACAAGCCCGTACGGGCGCTCAGCGGTTGGCGGGTGTGGCGGGTGTCCGGGCGCAGCCATGAGGTCTGATCGACT  
TAGAGGATCGATCCCGCCCGGACGAACAACTGACTACGACATCTCTGCCCTTCTTCCGGGGCAGTGCATGTAATCCCTTCAGTTG  
GTTGGTACAACCTGCCAAGTGGGCCCTGTTCCACATGTGACACGGGGGGGACCAACACAAGGGGTTCTCTGACTGTAGTTGACATCCT  
TATAAATGGATGTGCACATTTGCCAAGCTGAGTGGCTTTTATCCTGGAGCAGACTTTGCAAGTCTGTGGACTGCAACACAACATTCGCTTTATG  
TGTAACCTTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCAGGGGCCAGGAAGACTACGGGAGGCTACACCAACGTCA  
ATCAGAGGGGCTGTGTAGCTACCGATAAGCGGACCTCAAGAGGGCATTAGCAATAGTGTATAAGGCCCTTGTAAACCTAAACGGGT  
AGCATATGCTTCCCGGTAGTAGTATATATCTCCAGACTAACCTAATCAATAGCATATGTTACCAACGGGAAGCATATGCTATCGAATTAGG  
GTTAGTAAAGGGTCTAAGGAACAGCGATATCTCCACCCATGAGCTGTCACGGTTTTTATTACATGGGGTCAAGATTCCACGAGGGTAGT  
GAACCATTTTGTGACAAAGGCGAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACCTCTCTGATCTTCCGCTGCTTTCATTCTCCTTCGT  
TTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGTTTTAGGTGACGCCCCAGAAATAAATTT  
GGACGGGGGTTCAAGTGGTGGCATTGTGCTATGACACCAATATAACCCCTCACAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACAT  
TCTGAATATCTTAAACAATAGAATCCATGGGGTGGGACAAGCCGTAAGACTGGATGTCATCTCACAGAAATTTATGGCTATGGGCAACAC  
ATAACTCTAGTCAATATGATACTGGGTTATTAAGATGTGTCACAGGAGGACCAAGACAGGTGAACCATGTTGTACACTATTTGTAACA  
AGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTTAACACCCCGAAAATTAACAGGGGCTCCACGCCAATGGGG  
CCATAAACAAGACAAGTGCCACTCTTTTTTTGAAATTTGGAGTGGGGCACGCGTACGCCCCACACGCCGCCCTGCGGTTTTGGA  
CTGTAAATAAGGGTGTAAATAACTGGCTGATTGTAACCCCGTAACCACTGCGGTCAAACCACTTGCACAAAACCACTAATGGCACCCCG  
GGGAATACCTGCATAAGTAGGTGGCGGGCCAAAGATAGGGGCGGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCCTGAGCG  
CCAAGCACAGGGTGTGGTCCCTATATTACAGAGTGGCTGAGAGCAGCGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAATATC  
GGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAG  
ATATGCTATCCTAATTTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATGCTAT  
CCTAATCTGATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAATAT  
CTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAG  
CATATGCTATCCTAATCTATATCTGGGTAGTATGCTATCCTAATTTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTA  
TCCTAATCTATATCTGGGTAGTATGCTATCCTAATCTGATCCGGGTAGCATATGCTATCCTCATGATATACAGTCAAGTATGATACCCAGTA  
GTAGTGGAGTGCATCTTTCATATGCCATGCCCGCACCTCCCAAGGGGGCGTGAATTTTCGCTGCTTGTCCCTTTCCTGCTGGTTGCTCCCA  
TTCTTAGGTGAATTTAAGGAGGCCAGGCTAAAGCCGTCGCATGTCTGATTGCTCACCAGGTAATGTCGCTAATGTTTTCCAACGCGAGAAGG  
GTGGAGCGGAGCTGAGTACGTAACAATGGGTATGCCCAATGCCCATGTTGGGAGGACGAAAATGGTGAACAGACAGATGGCCA

GAATACACCAACAGCAGCATGATGTCTACTGGGATTATTCTTTAGTCGGGGGAATACACGGCTTTAATACGATTGAGGGCGTCTCCTA  
ACAAGTTACATCACTCCCTGCCCTTCCCTCACCCCTCATCTCCATCACCTCCTCATCTCCGTCATCTCCGTCATCACCTCCGCGCGAGCCCTT  
CCACCATAGGTGAAACCGGGGAGGCAAACTACTCCATCGTCAAAGCTGCACACAGTACCCTGATATTGACAGGTAGGAGCGGGCTTTGTC  
ATAACAAGTCTTAATCGCATCTTCAAACCTCAGCAAAATATGAGTTGTAAAAAGACCATGAATAACAGACAATGACTCCCTTAGCGG  
GCCAGGTTGTGGCCGGTCCAGGGCCATTCCAAAGGGGAGACACTCAATGGTGAAGACGACATTGTGAATAGCAAGGCGAGTCCG  
TCGCCTTAGGTTGTAAGGGAGGTTACTACTCCATATACGAACACACCGGCGACCCAAGTTCCCTCGTCGGTAGTCTTTCTACGTGACT  
CCTAGCCAGGAGAGCTTAAACCTTCTGCAATGTTCTCAAATTTGCGGTTGGAACCTCCTTGACCAGGATGCTTCCAAACCCCTCCTTT  
TTTGGCCTGCCTCCATCACCTGACCCCGGGTCCAGTGCTTGGCCCTTCTCCTGGGTCATCTGCGGGGCCCTGCTCTATCGCTCCCGG  
GGGCACGTCAAGGCTCACCATCTGGGCCACCTTCTTGGTGGTATTCAAATAATCGGCTTCCCTACAGGGTGGAAAAATGGCCTTCTACCTG  
GAGGGGGCTGCGCGGTGGAGACCCGGATGATGACTGACTACTGGGACTCCTGGGCTCTTTTCTCCACGTCCACGACCTCTCCCC  
TGCTCTTTACGACTTCCCCCTGGCTCTTTACGTCTCTACCCCGGGCGCTCCACTACCTCCTCGACC CGGCTCCACTACCTCCT  
CGACCCCGGCTCCACTGCCTCCTCGACCCCGGCTCCACCTCCTGCTCCTGCCCTCCTGCTCCTGCCCTCCTCCTGCTCCTGCCCT  
CCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTCCTGCTC  
CTGCCCTCCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCT  
TCTGCTCCTGCCCTCCTGCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCT  
GCCCCCTGCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTCCTGCCCTC  
CTCCCGCTCCTGCTCCTGCTCCTGTTCCACCGTGGGTCCTTTGACGCCAATGCAACTTGGACGTTTTTGGGGTCTCCGGACCAATCTCTA  
TGCTTTGGCCCTGATCCTGAGCCGCCGGGGTCTGGTCTTCCGCTCCTCGTCTCCTCTTCCCCGCTCCTCGTCCATGGTTATCAC  
CCCCTCTTTGAGGTCACCTGCCCGGAGCCTTCTGGTCCAGATGTCTCCCTTCTCCTTAGGCCATTCCAGTCTCTACTCCTGGC  
CCCTCGCAGACATGATTACACTAAAAGAGATCAATAGACATCTTTATTAGCAGCGCTCAGTGAATACAGGGAGTCCAGTCCGCC  
TCCAACAGCCCCCACCCTCATCCCTTATGGTCTGTCAGACAGATCCAGGTCTGAAAATCCCATCCTCCGAACCATCCTCGTCT  
CATCACAATTAATCGCAGCCGGAAAACCTCCGCTGAACATCTCAAGATTGGTCTGAGCTCAAGCCAGGCTCAAATTCCTGTC  
CCCTTTTGTGAGCGGTAGGGATGGGATTCTCGGACCCCTCCTCTTCTTCAAGTCAACAGCAGAGATGCTACTGGGCAACGG  
AAGAAAAGTGGGTGCGGCCTGTGAGGATCAGCTTATCGATGATAAGCTGTCAAACATGAGAATCTTGAAGACGAAAGGGCTCGTATAC  
GCCTATTTTATAGTTAATGTATGATAATAATGGTTCTTAGACGTGAGTGGCACTTTTGGGGAATGTCCGCGAACCCCTATTTGTTA  
TTTTCTAAATACATTCAAATATGATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATTGAAAAAGGAAGATGATGATTCAAC  
ATTTCCGTGTCGCCCTTATCCCTTTTTGCGGCATTTTGCCTCCTGTTTTGCTCACCCAGAACGCTGGTGAAGTAAAAGATGCTGAAGA  
TCAGTTGGTGCAGAGTGGTTACATCGAAGTGGATCTCAACAGCGGTAAGATCCTTGGAGTTTTGCCCCGAAGAAGTTTTCCAATGA  
TGAGACTTTTAAAGTCTGTATGTGGCGCGGTATTATCCCGTGTGACGCCGGGCAAGAGCAACTCGGTGCGCCGATACACTATTCTCAGA  
ATGACTTGGTTGAGTACTACCAGTACAGAAAAGCATCTTACGGATGGCATGACAGTAAAGAAATGATGAGTGTCCATAACCATGAGTG  
ATAACACTCGGCGCAACTTACTCTGACAACGATCGGAGGACGGAAGGAGCTAACCCTTTTTTGCACAACATGGGGATCATGTAACCTGC  
CTTGATGCTTGGGAACCGGAGCTGAATGAAGCCATACCAACGACGAGCGTGACACCACGATGCCTGACGAATGGCAACAACGTTGCGCA  
AACTATTAAGTGGCAACTACTTACTAGCTTCCCGGAACAATAAGACTGGATGGAGGGGATAAAGTTGACAGGACCCTTCTGCGCT  
CGGCCCTCCGGCTGGTGGTTATTGCTGATAAATCTGGAGCCGGTGAAGCGTGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGG  
TAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGAGTCAAGCAACTATGGATGAACGAAATAGACAGATGCTGAGATAGGTGCCTCACT  
GATTAAGCATTGGTAAGTGTGACAGCAAGTTTACTCATATATACTTTAGATTGATTTAAAACCTCATTTTAATTTAAAAGGATCTAGGTGAAGT  
CTTTTTGATAATCTCATGACCAAAATCCCTTAAGTGAAGTTTTCGTTCCACTGAGCTCAGACCCGCTAGAAAAGATCAAAGGATCTTCTGAG  
ATCCTTTTTTTGCAGGTAATGCTGCTTGCACAAAACCAACCCGCTACCCAGCGTGGTTTTTTTGGCCGATCAAGCAACTCCAACT  
TTTTTCCGAAGGTAAGTGGCTTCCAGCAGAGCGCAGATACCAACTGTCTTCTAGTGTAGCCGATGTTAGGCCACCCTTCAAGAAGTCTG  
TAGCACCGCTACATACCTCGCTCTGCTAATCCTGTACCAGTGGCTGCTGCCAGTGGCGATAAGTCTGTCTTACCAGGTTGGACTCAAGA  
CGATAGTACCAGGATAAGGCGCAGCGGTGCGGGTGAACGGGGGTTCTGTCACACAGCCCAAGTTGGAGCGAACGACCTACACCGAACTG  
AGATACCTACAGCGTGAAGATGAGAAAAGCGCCACGCTTCCGGAAGGGAGAAAAGCGGACAGGTATCCGTAAGCGGCAGGGTCGGAACA  
GGAGAGCTGCAAGGAGCTTCCAGGGGGAACCGCTGTATCTTATAGCTCCTGCGGTTTTCGCCACCTTACTGCTGAGCGTGAATTT  
TGTGATGCTCCTCAGGGGGGGGAGCCTATGAAAAACGCCAACAACGCGGCTTTTTACGGTTCTGCGCTTTTGGCCTTGAAGCTG  
TCCCTGATGGTCTCATCTACCTGCCGACAGCATGGCTGCAACGCGGGCATCCGATGCCGCCGAAGCGAGAAGATCATAATGGG  
AAGGCCATCCAGCCTCGCTGCAATCTGTCGACCTGAAATTTACCGGGTAGGGGAGCGCTTTTCCCAAGGCACTGAGGATGCGCT  
TTAGCAGCCCGCTGGGCACTTGGCGCTACACAAGTGGCTTGGCTCGCACATCCACATCCACCGTAGGCGCAACCGGCTCCG  
TTCTTTGGTGGCCCTTCCGCGCCACTTACTCCTCCCTAGTCAGGAAGTTCCCCCGCCCGCAGCTCGGCTGTGAGGACGTGAC  
AAATGGAAAGTAGCAGCTCACTAGTCTCGTGCAGATGACAGCAGCTGAGCAATGGAAGCGGTAGGCCCTTTGGGCGAGCGCCAAATA  
GCAGCTTTGCTCCTTCTGCTTCTGGGCTCAGAGGCTGGGAAGGGTGGTCCGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGCG  
GGCGCCGAAGGCTCCTCCGAGGCCCGGCTTCTGCAGCTTCAAAGCGCACGTCTGCCGCGCTTCTCCTCTTCTCATCTCCGGG  
CTTTGACCTGCATCCATCTAGATCTCGAGCAGCTGAAGCTTACCATGACCGAGTACAGCCACCGGTGCGCTCGCCACCCGCGACGAG  
TCCCCAGGGCGTACGACCCCTCGCCCGCGCTTCCCGACTACCCCGCCACGCGCCACACCGTGCATCCGGACCGCCACATCGAGCGG  
GTCACCGAGTGAAGAAGCTTCTCCTACGCGCGTGGGCTCGACATCGGCAAGGTGTTGGTTCGCGGACGACGCGCCCGCGGTGGCGGT  
CTGGACCACCGCGAGAGCGTGAAGCGGGGGCGGTGTTCCGCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCC  
GCGCAGCAACAGATGGAAGGCTCCTGGCGCGCACCGGCCAAAGGAGCCCGCTGGTTCTGCCCACCGTGGCGTCTGCCCGACC  
ACCAGGGCAAGGGTCTGGCAGCGCGCTGCTCCTCCGGAGTGGAGGCGGGCGAGCGCGCGGGGTGCCGCTTCTGGAGACCTC  
CGCGCCCCGCAACTCCCTTCTACGAGCGGCTCGGCTTACCGTACCCGCGACGTCGAGGTGCCGAAGGACCGCGCACCTGGTGCA  
TGACCCGAAGCCCGGTGCCTGACGCCCGCCACGACCCGACGCGCCGACCGAAAAGGAGCGCACGACCCCATGCATCGATGATACG  
ATCCCCGGGATGCAGAAATGATGATCTATAAACAATAAAGATGTCCACTAAATGGAAGTTTTTCTGTACTACTTTGTTAAGAAGGGTGA  
ACAGAGTACCATTTTGAATGGAAGGATTGAGCTACGGGGGGGGTGGGTTGGGTTGGGATGATAAATGCTCTTTACTGAAAGCTC  
TTACTATTGCTTTATGATAATGTTTATAGTTGGATATCATAATTTAAAACAAGCAAAACAAATTAAGGGCCAGCTCATTCTCCCACTCATGATC  
TATAGATCTATAGATCTCTGTTGGATCATTGTTTTCTTCTGATTCCACTTTGTGGTTCTAAGTACTGTGGTTTCAAATGTGTCAGTTTCATA  
GCCTGAAGAACGAGATCAGCAGCCTGTGTTCCACATACACTTACTTCTAGTATTGTTTTGCCAAGTCTAATCCATCAGAAAGCTGGTCCGACC  
AATTCATGTTTTGACAGTTATCATCGCAGATCCGGCAACGTTGTTGCCATTGCTGACGGCGCAGAAGTGGTAGGTATGGAAGATCTATAC  
ATTGAATCAATATTGGCAATTAGCCATATTAGTCTGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGATCTATATCATAA

TATGTACATTTATATTGGCTCATGTCCAATATGACCGCCAT

## 1.2 pCEP4 L1-ORFeus (1-17793bp)



| Features            | Regions (bp) |
|---------------------|--------------|
| CMV promoter        | 30-605       |
| ORF1 (L1-ORFeus)    | 676-1692     |
| ORF2 (L1-ORFeus)    | 1756-5580    |
| GFP-CT              | 5998-6382    |
| HBG-intron          | 6383-7282    |
| GFP-NT              | 7283-7826    |
| CMV promoter        | 7827-8446    |
| SV40 poly(A) signal | 8526-8659    |
| EBV-oriP            | 9388-11177   |
| EBNA1               | 11479-13404  |
| AmpR                | 14030-14890  |
| pUC origin          | 15061-15649  |
| PuroR               | 16383-16982  |

GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGTTACGTAACCTACGGT  
AAATGGCCCCGCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC  
ATTGACGTCAATGGTGGAGTATTACGGTAACTGCCACTTGGCAGTACATCAAGTGATCATATGCCAAGTCGCCCCCTATTGACGTCAA  
TGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTTGGCAGTACATCTACGTATTAGTCATCGCTATT  
ACCATGGTGATGCGGTTTTGACAGTACACCAATGGGCGTGGATAGCGGTTTACTCACGGGGATTCCAAGTCTCCACCCCATTTGACGTCAA  
TGGGAGTTTGTGGCACCAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGGGTAGGCGGTGAC  
GGTGGGAGGCTTATATAAGCAGAGCTCGTTTGTAGTAACCGTCAAGTCTCTAGAAAGCTGGTACCAGCTGCTAGCAAGCTTGTAGCGGCCG  
GTTTAAACTTAATTAAGCCACCATGGGCAAGAAGCAGAACCBCAAGACCGGCAACAGCAAGACCCAGAGCGCCAGCCCCCCCCCAAGGA  
GCGCAGCAGCAGCCCCGCCACCGAGCAGAGCTGGATGGAGAAGCATTGACGAGCTGCGCGAGGAGGGCTTCCGCGCAGCAACTACA  
GCGAGCTGCGCGAGGACATCCAGACCAAGGGCAAGGAGTGGAGAATTCGAGAAGAACCTGGAGGAGTGATCACCCGATACCAACA  
CCGAGAAGTGCTGAAGGAGCTGATGGAGCTGAAGACCAAGGCCGCGAGCTGCGCGAGGAGTGCCGCGAGCTGCGCAGCCGCTGCGA  
CCATTGGAGGAGCGGTGAGCGCCATGGAGGACGAGATGAAGCAGATGAAGCGCGAGGGCAAGTTCGCGAGAAGCGCATCAAGCGCA  
ACGAGCAGAGCCTGCGAGGATCTGGGACTACGTGAAGCGCCCCAACCTGCGCCTGATCGCGCTGCCCGAGAGCGAGCTGGAGAACGGC  
ACCAAGCTGGAGAACCCTGCAGGACATCATCCAGGAGAATTTCCCAACCTGGCCCGCCAGGCCAACGTGCAGATCCAGGAGATCCAG  
GCAACCCCGCCAGCTACAGCAGCCGCGCCGCCACCCCGCCACCTCGTGCCTTCAACAAGGTGGAGATGAAGGAGAGATGCTG  
CGCGCGCCGCGAGAAGGGCCGCGTACCCTGAAGGGCAAGCCATCCGCTCAACCGCGACCTGAGCGCGGAGCCCTGACGCGCC  
GCCGCGAGTGGGGCCCCATTTCAACATCTGAAGGAGAAGAACTTCCAGCCCCGATCAGCTACCCCGCAAGCTGAGCTTTCATCAGCGA  
GGGCGAGATCAAGTACTTATCGACAAGCAGATGCTGCGGACTTCGTGACCACCCGCCCCGCTGAAGGAGCTGCTGAAGGAGCCCT  
GAACATGGAGCGCAACAACCGCTACCAGCCCTGCAGAACCAGCCAAAGATGTAAGACCATCGAGACTAGGAAGAACTGCATCAACTAAT  
GAGCAAATCAGGCGCGCCCATCATAATGACCGGCAGCAACGCCACATCACCATCTGACCTGAACATCAACGGCTGAACAGCGCCAT  
CAAGCGCCACCGCTGAGCTGGATCAAGAGCCAGGACCCAGCGTGTGCTGCATCCAGGAGACCCACCTGACCTGCCGCGACCCC  
ACCGCTCAAGATCAAGGGCTGGCCGAAGATCTACCAGGCCAACGGCAAGCAGAAGAAGGCCGGCTGGCCATCTGTTGAGCGACAAAG  
ACCGACTTCAAGCCCAAGATCAAGCGCGACAAGGAGGGCCACTACATCATGGTGAAGGGCAGCATCCAGCAGGAGGAGCTGACCATC  
CTGAACATCTACGCCCCCAACACCGGTGCCCCCGCTTTCATCAAGCAGGTGCTGAGCGACCTGCAGCGGACCTGGAGAGCCACACCCCTG  
ATCATGGGCGACTTCAACACCCCTGAGCACCCCTGGACCGCAGCACCCGCGAGAGGTGAACAAGGACACCCAGGAGCTGAACAGCGCC  
CTGCACCGGCGACCTGATCGACATCTACCGACCCCTGCACCCCAAGAGCAGGAGTACACCTTTCAGCGCCCCCAACACACCTACA  
GAAGATCGACCAACATCGTGGCAGCAAGGCCCTGCTGAGCAAGTGCAAGCGCACCCGAGATCATCAACAACTACCTGAGCGACCAAGCG  
CCATCAAGCTGGAGCTGCGCATCAAGAACCTGACCCAGAGCCGAGCACCCCTGGAAGCTGAACAACCTGCTGCTGAACGACTGTGGG  
TGACAACGAGATGAAGGCCGAGATCAAGATGTTCTTGAACCAACGAGAACAAGGACACCCATCCAGAACCTGTGGGACGCCTTCAA  
GGCCGTGTGCCGCGCAAGTTCATCGCCCTGAACGCTTACAAGCGCAAGCAGGAGCGCAGCAAGATCGACACCCCTGACCGAGCAGCTGAA  
GGAGCTGGAGAAGCAGGAGCAGACCCACAGCAAGGCCAGCCGCGCCAGGAGATCACCAAGATCCGCGCCGAGCTGAAGGAGATCGAGA  
CCCAGAAGACCTGCAGAAGATCAACGAGTCCGGAAGCTGTTCTTCGAGCGCATCAACAAGATCGACCGCCCCCTGGCCCGCTGATCAA  
GAAGAAGCGCGAGAAGAACCAGATCGACACCATCAAGAACGACAAGGGCGGACATCACCCAGCCACCCAGATCCAGACCCATCCG  
CGAGTACTACAAGCACCTGTACGCCAACAAGCTGGAGAACCTGGAGGAGATGGACACCTTCTGGACACCTACACCCCTGCCCGCCTGAAC  
CAGGAGGAGGTGGAGAGCTGAACCGCCCCATCACCGCAGCGAGATCGTGGCCATCATCAACAGCTGCCACCAAGAAGAGCCCCGG  
CCCCGACGGCTTACCAGCGGAGTTTACAGCGCTACAAGGAGGAGCTGGTCCCTTCTGCTGAAGCTGTTCCAGAGCATCGAGAAGGA  
GGGATCTGCCAAGACTTACAGAGGCCAGCATCATCTGATCCCAAGCCCGGCCGCGACACCAAGAAGGAGAATTCGCCCC  
CATCAGCTGATGAACATCGACGCCAAGATCTTGAACAAGATCTGGCAACCGCATCCAGCAGCATCAAGAAGCTGATCCACCAGCACC  
AGGTGGGCTTATCCCGGGATGCAAGGCTGGTTCAACATCCGCAAGGATCAACGTGATCCAGCAGCATCAACCGCGCCCAAGGACAAGAA  
CCACATGATCATCAGCATCGACGCGGAGAAGGCCCTTCGACAAGATCCAGCAGCCCTTCTGCTGAAGACCTGAACAAGCTGGGATCGAC  
GGCCTACTTCAAGATCATCCGCGCATCTACGACAAGCCACCGCAACATCATCTGACGGCCAGAAGCTGGAGGCTTCCCCTGA  
AGACCGGACCGCTCAGGGCTGCCCTGAGCCCCCTGCTTCAACATCGTGTGAGGAGTGTGCGCCGCGCATCCGCCAGGAGAAG

GAGATCAAGGGCATCCAGCTGGGCAAGGAGGAGGTGAAGCTGAGCCTGTTCCGCC **TA** GACATGATCGTGTACCTGGAGAACCCCATCGT  
AGCGCCAGAACCTGCTGAAAGCTGATCAGCAACTTCAGCAAGGTGAGCGGTACAAGATCAACGTGCAGAAGAGCCAGGCCCTCTGTACA  
CCAACAACCGCCAGACCGAGAGCCAGATCATGGCGAGCTGCCCTTACCATTGCTAGCAAGCGCATCAAGTACCTGGGCATCCAGCTGAC  
CCGCGAGCTGAAGGACCTGTTCAAGGAGAAGTACAAGCCCTGCTGAAGGAGATCAAGGAGGAGACCAACAAGTGAAGAACATCCCCT  
CAGCTGGGTGGGCCATCAACATCGTGAAGATGGCCATCTGCCAAGGTGATCTACCCTTCAACGCCATCCCATGGACCTGATCAAGC  
ACCTTCTCACCGAGCTGGAGAAGACCACCCTGAAGTTCATCTGGAACCAGAAGCGCGCCGCATCGCCAAGAGCATCCTGAGCCAGAAGA  
ACAAGGCCGGCGGCATCACCTGCCGACTTCAAGCTGTACTACAAGGCCACCGTGACCAAGACCCTGGTACTGGTACCAGAACCCTG  
ATATCGACCAGTGAACCCGACCGAGCCAGCGAGATCATGCCACATCTACAACCTACCTGATCTTCGACAAGCCCGAGAAGACAAGCAG  
TGGGGCAAGGACAGCCTGTTCAACAAGTGGTGTGGGAGAAGTGGTGGCCATCTGCCGAAGCTGAAGCTGGACCCCCTTCTGACCCCC  
TACACCAAGATCAACAGCCGCTGGATCAAGGACCTGAACGTGAAGCCCAAGACCATCAAGACCCTGGAGGAGAAGCTGGGCATCACCATCC  
AGGACATCGGCCGTGGGCAAGGACTTCATGAGCAAGACCCCAAGGCCATGGCCACCAAGGACAAGATCGACAAGTGGGACCTGATCAAGC  
TGAAGAGCTTCTGCACCGCCAAGGAGACCACCTCCGCGTGAACCGCCAGCCACCACCTGGGAGAAGATCTTCCGCACCTACAGCAGCG  
ACAAGGGCTGATCAGCCGCATCTACAAGAGCTGAAGCAGATCTACAAGAAGAAGACCAACAACCCCATCAAGAAGTGGGCCAAGGACAT  
GAACCGCCATTCAGCAAGGAGGACATCTACGCCGCCAAGAAGCATATGAAGAAGTGCAGCAGCAGCCTGGCCATCCGCGAGATGCAGATC  
AAGACCACCATGCGCTACCACCTGACCCCCGTGCGCATGGCCATCATCAAGAAGAGCGGCAACAACCCGCTGCTGGCGCGGTGCGGGCAG  
ATCGGCCCTGCTGACTGCTGGTGGGACTGCAAGCTGGTGCAGCCCTGTGAAGAGCGTGTGGCGCTTCTGCGGACCTGGAGCT  
GGAGATCCCTTCGACCCGCCATCCCCTGCTGGGCATCCCCCAAGGAGTACAAGAGCTGCTGCTACAAGGACACCTGCACCCGATG  
TTCATCGCCGCCCTGTTACCATCGCCAAGACCTGGAACAGCCCAAGTCCCCCACCATGATCGATTGGATCAAGAAGATGTGGCAGATCTA  
CACCATGGAGTACTAGCCGCCATCAAGAAGCAGGAGTTCATCAGCTTCTGGGCACCTGGATGAAGCTGGAGACCATCATCTGAGCAAG  
CTGAGCCAGGAGCAGAAGACCAAGCACCAGCATCTTACGCTGATCGCGGCCAACGGCGCGCAGCGCGCGCCGCGCAGCCATCACCATCA  
CCATCACCATCACCTGGAAGTCTGTTCAGGGGCCCTGGAAGTCTGTCCAGGGGCCCTTAAGGAACAGAAGCTAATCTCAGAAGAA  
GACCTGGAACAGAAGCTAATCTCAGAAGAAGACCTGGACTACAAGACCATGACGGTGATTATAAGATCATGACATCGATTACAAGGATGAC  
GATGACAAGTAGATTAAATACAATGAGATCAGATGACATGGACACAGGAAGGGGAATATCACACTCTGGGGACTGTGGTGGGTGCGGGGAGG  
GGAGGGATAGCATTGGGAGATATACCTAATGCTAGATGACACATTAGTGGGTGCAGCGCACCAGCATGGCAGATGTAACGACGGATCGATC  
CGAACAAAGCAGCC**AACACCCGTGCGTTTTATTCTGCTTTTTATTGCGGATCCCTCAGAAGAACTCGTCAAGAAGCGGATAGAAGGCGA**  
**TGCGCTGCGAATCGGGAGCGGGATACCGTAAAGCAGGAGGAAGCGGTACGCCATTCCGCCCAAGCTTTCAGCAATATCACGGGTA**  
**GCCAACGCTATGCTGATAGCGGTGCGCCGCTTACTTTGACAGCTGCTCCATGCCGAGAGTATCCCGCGCGGCTCACGAACTCCAG**  
**CAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTGGCTCAGGGCCGAGTGGGTGCTCAGGTAGTGGTTGCGGCGAGCAGCAGCGGG**  
**CGTCCCGATGGGGTGTCTGCTGGTAGTGGTGGCCAGGTGAGTCCAGGAGATGTTTACGACTGTTGCCTTCTAGCTCGAGGCAACTT**  
AGACAAGTGAATGATCTGAGCAGCAGCGGTGTGAGCTGTTGAAGATACTGGGGTGGGGTGAAGAACTGCAGAGGACTAACTGG  
GCTGAGACCCAGTGGCAATGTTTAGGGCCTAAGGAATGCCCTGAAATCTAGATGGACAATTTGACTTTGAGAAAAGAGAGGTGGAAT  
GAGGAAATGACTTTTCTTATTAGATTTCCGTAGAAAAGAACTTTCATCTTCCCTATTTTTGTTATTGTTTTAAACATCTATCTGGAGGCGAG  
GACAAGTATGGTCATTAATAAAGATGCAGGCGAGAAGGCATATATGGCTCAGTCAAAGTGGGAACTTTGGTGGCCAAACATACATTGCTAAGG  
GTTGAGGAAACAATTGAACATTTGGGCTGGAGTAGATTTGAAGATCAGCTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG  
CGTGTGTTG  
TAAATATGGCCAGTACTGTGCTGCAAGAAGAACAACTACCTGCATTAATGGGAAAGCAAATCTCAGGCTTTGAGGGAAGTAAACATAGG  
CTTGATTCTGGTGGAAGCTGGGTG  
TCTCAACAG**CTGCACGCTGCCGCTCGATGTTGTGGCGGATCTGAAGTTCACCTTGATGCCGTTCTTCTGCTTGTGCGGCATGATAGA**  
**CGTTGTGGCTGTTGTACTCCAGCTTGTGCCCGAGATGTTGCCGCTCCTTGAAGTCGATGCCCTCAGCTGATGCGGTTCCAC**  
**CAGGGTGTGCCCTCGAATTCACCTCGCCGCGGGTCTTGATGTTGCCGCTGCTCTTGAAGAAGATGGTGGCTCCTGAGCGGATCC**  
**GGCATGGCGGACTGAAGAAGTCTGCTGCTTTCATGTGGTGGGGTAGCGGCTGAAGCACTGCACGCGTAGGTGAGGTGGTCAAG**  
**AGGGTGGGCGAGGGCAGGGCAGCTTGGCGGTGGTGCAGATGAACCTCAGGGTCAAGTGGCGTAGGTGGCATGCCCTCGCCCTCGC**  
**CGGACACGCTGAACCTGTGGCCGTTACGCTGCCGCTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTGCTC**  
**ACCATGGTGGCAATTCGAAGCTTGAGCTCGAGCTGAGTCCGGTAGCGCTAGCGGATCTGACGGTCACTAAACCAGCTCTGCTTATATA**  
GACCTCCACCTGACACGCTACCCGCCCATTTCGTCATGTCGGCGGAGTGTGTACGACATTTTGAAGTCCCGTGTATTGTGGGCCAAA  
ACAACCTCCCAATGACGTAATGCGGTTGGAGACTTGGAAATCCCGTGAAGTCAAACCGCTATCCACGCCCATTTGATGATGCCAAAACCGC  
ATCACCATGGTAATAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCATAAGGTGATGACTGGGCATAATGCCAGGCGGGC  
CATTTACCCTCATTGACGTCAATAGGGGGTACTTGGCATATGATACATTTGATGACTGCCAAGTGGGCAGTTTACCCTAATACTCCACCC  
ATTGACGTCAATGGAAGTCCCTATTGGCGTTACTATGGGAACATACGTCATTATTGACGTCAATGGCGGGGGTCTGGGCGGTGAGCCA  
GGCGGGCCATTTACCCTAAGTTATGTAACCGGAACTCCATATATGGGCTATGAACATGACCCCGTAATTTGATTACTATTAGCCCGGCAAT  
GTGCAGATGACCCATAAACTTAAAGTATAATAAGAGCTCAGGGTTCGAAATCGATAAGCTTGGATCCAGACATGATAAGATACATTGATGAT  
TTGGACAACCAACAAGTGAATGCAAGTGAATAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACATTATAAGCTGCAATA  
AACAAGTAAACAACAACAATTGCATTATTTATGTTTTCAGGTTACAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAATG  
TGGTATGGCTGATTATGATCCGGCTGCCTCGCGCTTTCGGTGTGACGGTGAACCTCTGACACATGCAGCTCCCGGAGACGGTACAG  
CTTGCTGTAAGCGGATCGCCGGGAGCAGACAAGCCCGTCAAGGCGCGTCAAGCGGGTGTGGCGGGTGTGGGGGCGCAGCCATGAGGTGC  
ATCGACTCTAGAGGATCGATCCCGCCCGGACGAATAACCTGACTACGACATCTCTGCCCTTCTTCGCGGGGAGTGCATGTAATCCC  
TTCAGTTGGTTGGTACAACCTTGCACACTGGGCCCTGTTCCACATGTGACACGGGGGGGACCAAAACAAGGGGTTCTCTGACTGTAGTT  
GACATCCTTATAAATGGATGTCACATTTGCCAACACTGAGTGGCTTTCATCTGGAGCAGACTTTCAGTCTGTGGACTGCAACACAACATT  
GCCTTTATGTAACTCTGGCTGAAGCTCTTACCAATGCTGGGGACATGTACCCTCCAGGGGCCAGGAAGACTACGGGAGGCTACAC  
CAACGTCAATCAGAGGGGCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTATAAGGCCCCCTGTTAAACCT  
AAACGGGTAGCATATGCTCCCGGGTAGTAGTATACTATCCAGACTAACCTAATTAATAGCATATGTACCCAACGGGAAGCATATGCTATC  
GAATTAGGGTTAGTAAAGGGTCTAAGGAACAGCGATATCTCCACCCCATGAGCTGTCACGGTTTTATTACATGGGGTCCAGGATCCACG  
AGGGTAGTGAACCTTTAGTCAAGGGCAGTGGCTGAAGTCAAGGACGGGCGGAGTGAACCTCTCTGAATCTCGCTGACTTCTTCATTC  
TCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGTTTTAGGTGACGCCCCAGA  
ATAAAATTTGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCTCACAACCCCTTGGGAATAAATACTAGTGTAGGAA  
TGAACATTCGAATATCTTAAACATAGAAATCCATGGGGTGGGGACAAGCCGTAAGACTGGATGTCATCTCACAGCAATTTATGGCTATG  
GGCAACACATAATCTAGTGAATATGATACTGGGGTATTAAAGATGTGCCAGGCGAGGACCAAGACAGGTGAACCATGTTGTACTACTA  
TTTGTAAACAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTGTCTCTAACACCCCGAAAATTAACGGGGCTCCACGC





TCGAGCGGGTCACCGAGCTGCAAGAAGCTTCTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGG  
 GTGGCGGTCTGGACCACGCCGAGAGCGTCAAGCGGGGGCGGTGTTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCC  
 GGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGACCCGGCCAAAGGAGCCCGCGTGGTTCTGGCCACCGTCGGCGTCTC  
 GCCCACCACAGGGCAAGGTCTGGGCAGCGCCGTCGTCTCCCGAGTGGAGCGGCCGAGCGCGCCGGGTGCCCGCCTTCT  
 GGAGACCTCCGCGCCCGCAACCTCCCTTCTACGAGCGGCTCGGCTTACCCTGACCCGCGACGTCGAGGTGCCCGAAGGACCGCGCA  
 CCTGGTGATGACCCGCAAGCCCGGTGCCTGACGCGCCGCCACGACCCGAGCGCCGACCGAAAGGAGCGCACGACCCCATGCATCG  
 ATGATATCAGATCCCCGGGATGCAGAAATTGATGATCTATTAACAATAAAGATGTCCACTAAAATGGAAGTTTTCTGTGCATACTTTGTTAAGA  
 AGGGTGAGAACAGAGTACCTACATTTTGAATGGAAGGATTGGAGCTACGGGGTGGGGTGGGGTGGGATTAGATAAATGCCTGCTCTTAC  
 TGAAGGCTCTTACTATTGCTTTATGATAATGTTTCATAGTTGGATATCATAATTTAAACAAGCAAACCAAATTAAGGGCCAGCTCATTCTCCC  
 ACTCATGATCTATAGATCTATAGATCTCTCGTGGGATCATTGTTTTCTCTTGATTCCACTTTGTGGTTCTAAGTACTGTGTTTCCAATGTGT  
 CAGTTTCATAGCCTGAAGAACGAGATCAGCAGCCTCTGTTCCACATACACTTCACTCTCAGTATTGTTTTGCCAAGTTCTAATCCATCAGAAG  
 CTGGTCGACATTGGATTGGAAGTAGTATACTAACCTTACCTATTGCAATTCATGTTTGACAGCTTATCATCGCAGATCCGGGCAACGTTGTT  
 GCCATTGCTGCAGGCGCAGAAGCTGGTAGGTATGGAAGATCTATACATTGAATCAATATTGGCAATTAGCCATATTAGTCATTGGTTATATAGCATA  
 AATCAATATTGGCTATTGGCCATTGCATACGTTGATCTATATCATAATATGTACATTATATTGGCTCATGTCCAATATGACCGCCAT

**1.3 pCEP4 L1-ORFeus-ENm (H230A) (L1-ENm) and pCEP4 L1-ORFeus-RTm (D702Y) (L1-RTm) plasmids share the same sequences as pCEP4 L1-ORFeus except for the following minor key changes:**

|                      | EN (2443-2445 bp) | RT (3859-3861bp) |
|----------------------|-------------------|------------------|
| pCEP4 L1-ORFeus      | H230 (CAC)        | D702 (GAC)       |
| pCEP4 L1-ENm (H230A) | A230 (GCT)        | D702 (GAC)       |
| pCEP4 L1-RTm (D702Y) | H230 (CAC)        | Y702 (TAC)       |

## Supplementary Sequence 2. DNA sequences of endogenous human L1 (i.e., L1Hs and L1RP)

### 2.1 L1Hs

The human LINE-1 element (L1 Homo sapiens, or L1Hs) is the most active autonomous retrotransposon family in the human genome (it's got an ACG, making it an L1PA2).

| Features    | Regions (bp) |
|-------------|--------------|
| L1 5'UTR    | 1-907        |
| ORF1 (L1Hs) | 908-1924     |
| ORF2 (L1Hs) | 1988-5815    |
| L1 3'UTR    | 5816-6064    |

```
GGGAGGAGGAGCCAAGATGGCCGAATAGGAACAGTCCGGTCTACAGTCCCAGCGTGAGCGACGCAGAAGACGGGTGATTCTGCATTT
CCATCTGAGGTACCGGGTTCATCTCACTAGGGAGTGCCAGACAGTGGGCGCAGGCCAGTGTGTGCGCACCGTGCAGCGAGCCGAAGCA
GGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTGAGGGAGTTCCCTTTCCGAGTCAAAGAAAAGGGGTGACGGACGCACCTGGAAA
ATCGGGTCACTCCCACCCGAATATTGCGCTTTTCAGACCGGCTTAAGAAACGGCGCACCCAGAGACTATATCCCACACCTGGCTCAGAGGGT
CCTACGCCACGGAATCTCCTGCTGATTGCTAGCACAGCAGTCTGAGATCAAAGTGCAGGCGGCAACGAGGCTGGGGGAGGGGCGCCCGCC
ATTGCCAGGCTTGCTTAGGTAACAAGCAGCCGGGAAGTCTGAACTGGGTGGAGCCACCACAGCTCAAGGAGGCTGCCTGCCTCTG
TAGGCTCCACCTCTGGGGCAGGCGACAGACAAAACAAAAGACAGCAGTAACCTCTGCAGACTTAAGTGTCCCTGTCTGACAGCTTTGAAG
AGAGCAGTGGTTCTCCAGCACGCAGCTGGAGATCTGAGAACGGGCGAGACTGCCTCCTCAAGTGGGTCCCTGACCCCTGACCCCGAGCA
GCCTAAGTGGGAGCCACCCCGAGCAGGGGCACACTGACACCTCACACGGCAGGGTATTCCAACAGACCTGCAGCTGAGGGTCTGTCTG
TTAGAAGGAAAACAAACACAGAAAGGACATCTACACCGAAAACCCATCTGTACATCACCATCATCAAAGACAAAAGTAGATAAAACCAAA
AGATGGGAAAAAACAGAACAGAAAAAAGTGGAACTCTAAAACGCAGAGCGCCTCTCCTCCTCAAAGGAACGCAGTTCTCACCAGCAAC
AGAACAAGCTGGATGGAGAATGATTTGACGAGCTGAGAGAAGAAGGCTTCAGACGATCAAATTACTCTGAGCTACGGGAGGACATTCAAA
CCAAAGGCAAGAAGTTGAAAACCTTTGAAAAAATTTAGAAGAATGTATACTAGAATAACCAATACAGAGAAGTGTAAAGGAGCTGATGGA
CTGAAAACCAAGGCTCGAGAACTACGTGAAGAATGCAGAGCCCTCAGGAGCCGATCGCATCAACTGGAAGAAAAGGGTATCAGCAATGGAA
GATGAAATGAATGAAATGAAGCGAGAAGGGAAGTTAGAGAAAAAGAATAAAAAGAAATGAGCAAAGCCTCAAAGAAATATGGGACTATGTG
AAAAGACCAATCTACGCTGATTGGTGTACCTGAAAGTGATGTGGAGAATGGAACCAAGTTGAAAACACTCTGCAGGATATTACAGGAG
AACTCCCAATCTAGCAAGGCAAGGCCAACGTTTCAAGTTCAGGAAATACAGAGAAGCCACAAGATACTCCTCGAGAAGAGCAACTCCAAG
ACACATAATTGTGAGATTCCAAAGTTGAAATGAAGGAAAAAATGTTAAGGGCAGCCAGAGAGAAAGGTGGGGTTACCCCTCAAAGGAAAGC
CCATCAGACTAACCGGGATCTCTGGCAGAAAACCTACAAGCCAGAAGAGAGTGGGGGCAATATTCAACATTTAAAGAAAAGAAATTTTC
AACCCAGAATTTTATATCCAGCCAAAAGTTCATAAGTGAAGGAGAAAATAAAATACTTTATAGACAAGCAAAATGCTGAGAGATTTTGTCAAC
ACCAGGCTGCCCTAAAAGAGCTCTGAAGGAAGCGCTAAACATGGAAGGAACAAACCCGGTACCAGCCGCTGCAAAATCATGCCAAAATGTA
AAGACCATCGAGACTAGGAAGAAACTGCATCAACTAATGAGCAAAATCACCAGCTAACATCATAATGACAGGATCAAATTCACACATAACAAT
TAATTTAAATATAAATGGACTAAATTTCTGCAATAAAAGACACAGACTGGCAAGTTGGATAAAGAGTCAAGACCCATCAGTGTCTGTATTGAG
GAAACCCATCTCAGTGCAGAGACACATAGGCTCAAATAAAGGATGGAGGAAGATCTACCAAGCCATGGAAAACAAAAAAGGCAGG
GGTTGCAATCTAGTCTGTATAAACAGACTTTAAACCAACAAGATCAAAGAGACAAGAAGGCCATTACATAATGGTAAAGGGATCAAT
CAACAAGAGGAGCTAACTATCCTAAATTTATGCACCCAATACAGGAGCACCAGATTCATAAAGCAAGTCTCAGTGAAGCTTCAAAAGAGCT
TAGACTCCCACACATTAATAATGGGAGACTTTAACACCCCACTGTCAACATTAGACAGATCAACGAGACAGAAAGTCAACAAGGATACCCAGG
AATTGAACTCAGCTCTGCACCAAGCAGACCTAATAGACATCTACAGAACTCTCCACCCCAATCAACAGAATATACATTTTTTTCAGCACCACA
CCACACCTATTCCAAAATGACCACATAGTTGGAAGTAAAGCTCTCCTCAGCAAAATGTAAGAAACGAAATATAACAAACTATCTCAGACC
ACAGTGAATCAAAGTGAAGTCAAGGATTAAGAAATCTCACTCAAAGCCGCTCAACTACATGAAACTGAACAACCTGCTCCTGAATGACTACT
GGGTACATAACGAAATGAAGGCAGAAATAAGATGTTCTTTGAAACCAACGAGAACAAGACACCACATACCAGAATCTCTGGGAGCATTCA
AAGCAGTGTGTAGAGGGAAATTTATAGCACTAAATGCTTACAAGAGAAAGCAGGAAAGTCAAATGACACCCCTAACATCACAATTAAGA
ACTAGAAAAGCAAGAGCAAAACACATTCAAAGCTAGCAGAAGGCAAGAAATAACTAAAATCAGAGCAGAACTGAAGGAAATAGAGACACAAAA
AACCTTCAAATAATCAATGAATCCAGGAGCTGGTTTTTTGAAAGGATCAACAAAATGATAGACCGCTAGCAAGACTATAAAGAAAAAAGA
GAGAAGAAATCAATAGACACAATAAAAAATGATAAAGGGGATATCACACCGATCCACAGAAATACAAACTACCATCAGAGAATACTACAAACA
CCTCTACGCAATAAAGTAAAAATCTAGAAGAAATGGATACATCTCCTCGACACATACACTCTCCCAAGACTAAACCGGAAGAAGTTGAATCT
CTGAATAGACCAATAACAGGCTCTGAAATTTGGCAATAATCAATAGTTTACCAACCAAAAAGAGTCCAGGACCAGATGGATTCACAGCCGAAT
TCTACCAGAGGTACAAGGAGGAACTGGTACCATTCTTCTGAAACTATCCAAATCAATAGAAAAGAGGGAAATCCTCCCTAACTCATTTTATGA
GGCCAGCATATTCTGATACCAAGCCGGGCGAGACACAACCAAAAAGAGAAATTTAGACCAATATCCTTGATGAACATTGATGCAAAAATC
CTCAATAAAATACTGGCAACCGAATCCAGCAGCACATCAAAGGCTTATCCACCATGATCAAGTGGGCTTCATCCTGGGATGCAAGGCTGG
TTCAATATACGCAAAATCAATAATGTAATCCAGCATATAAACAGAGCAAAAGACAAAACCCATGATTATCTCAATAGATGCAAGAAAAGCCTTT
GACAAAATCAACAACCCCTCATGCTAAAACCTCAATAAATTAGGTATTGATGGGACGTATTTCAAATAATAAGAGCTATCTATGACAAAACCC
ACAGCCAAATCATACTGAATGGGCAAAAACCTGGAAGCATCCCTTTGAAAACCTGGCAAGACAGGGATGCCCTCTCACCCTCCTCATTTC
AACATAGTGTGGAAAGTTCTGGCCAGGCAATCAGGCAGGAGAAAGAAATAAAGGGTATTCAATTAGGAAAAGAGGAAATCCTCCCTGATCCT
GTTTGCAGACGATGATTGTTTATCTAGAAAACCCCATCGTCTCAGCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGTCTCAGGA
TACAAAATCAATGTACAAAATACAAGCATTCTTATACACCAACAACAGACAAACAGAGGCAAAATCATGGGTGAACCTCCATTACAATTG
CTTCAAAGAGAAATAAATACCTAGGAATCCAACCTTACAAGGGATGTGAAGGACCTTCTAAGGAGAACTACAACCACTGCTCAAGGAAATAAA
AGAGGACACAACAATGGAAGAACATTCCATGCTCATGGGTAGGAAGAATCAATATCGTGAATGGCCATAGCCCAAGGTAATTTACAGA
TTCAATGCCATCCCCTCAAGTACCATGACTTTTTCACAGAAATGGAAGAACTACTTTAAAGTTTCAATGGAACCCAAAAGAGCCCGCAT
CGCCAAAGTCAATCCTAAGCCAAAAGAACAAAGCTGGAGGCATCACACTACCTGACTTCAAATATACTACAAGGCTACAGAACCAAGCAGC
ATGGTACTGGTACCAAAACAGAGATATAGATCAATGGAACAGAACAGAGCCCTCAGAAATAATGCCGCATATCTACAATCTGTATCTTTGACA
AACCTGAGAAAAACAAAGCAATGGGAAAAGGATTCCCTATTTAAATAAATGGTGTGGGAAAACCTGGCTAGCCATATGTAGAAAAGCTGAAACTGG
ATCCCTTCTTACACCTTATACAAAATCAATTAAGATGGATTAAGATTTAAACGTTAGACCTAAAACCCATAAAAACCCCTAGAAGAAAACCTAG
```

GCATTACCATTGAGACATAGGCGTGGGCAAGGACTTCATGTCACAAACACCAAAGCAATGGCAACAAAAGCCAAAATTGACAAATGGGATC  
 TAATTAACATAAAGAGCTTCTGCACAGCAAAAAGAACTACCATCAGAGTGAACAGGCAACCTACACATGGGAGAAAATTTCCGCAACCTACTC  
 ATCTGACAAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAATTTACAAGAAAAAACAACAACCCCATCAAAAAGTGGGCGAAGGAC  
 ATGAACAGACACTTCTCAAAAAGACATTTATCGAGCAAAAAACACATGAAGAAATGCTCATCATCTGCCCATCAGAGAAATGCAAAATCA  
 AAACCATATGAGATATCATCTCACACCAGTTAGAAATGGCAATCATTAATAAAGTCAGGAAACAACAGGTGCTGGAGAGGATGGGAGAAATG  
 GAACACTTTTACACTGTTGGTGGGACTGTAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGATTCTCTCAGGGATCTAGAACTAGAATAAC  
 CATTGACCCAGCCATCCATTACTGGGTATATACCCAAAGACTATAAATCATGCTGTATAAAGACACATGCACACGTATGTTTATTGCGGCA  
 CTATTCACATAGCAAGACTTGGAAACCAACCAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAATACTA  
 TGCAGCCATAAAAAATGATGATTCATATCCTTTGTAGGGACATGGATGAAATTGGAACCATCATTCTCAGTAACTATCGCAAGAACAACAAAA  
 CCAAACACCCCATATTCTCACTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAATATCACACTTGGGGACTGTGGT  
 GGGGTCGGGGAGGGGGAGGGATAGCATTGGAGATATACCTAATGCTAGATGACACGTTAGTGGGTGCAGCGCACACGATGGCAGCATG  
 TATACATATGTAACCTACCTGCACAATGTGCACATGTACCCTAAAACCTTAGAGTATAATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
 TAAAA

## 2.2 L1RP

It's the prototypical active L1 in modern humans with full-length LINE-1, ORF1p and ORF2p proteins (it's 3' UTR contains an ACA, making it an L1PA1)

| Features    | Regions (bp) |
|-------------|--------------|
| L1 5'UTR    | 1-906        |
| ORF1 (L1RP) | 907-1923     |
| ORF2 (L1RP) | 1987-5814    |
| L1 3'UTR    | 5815-6019    |

GGGGGAGGAGCAAGATGGCCGAATAGGAACAGTCCGGTCTACAGTCCAGCGTGAGCGACGAGAAGACGGTGATTTCTGCATTC  
 CATCTGAGGTACCGGTTTCTACTAGGGAGTGCCAGACAGTGGCGCAGGCCAGTGTGTGCGCACCGTGCAGGAGCCGAAGCAG  
 GCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGTCCAGGAGTTCCTTTCCGAGTCAAAGAAAGGGGTGACGGACGCACCTGAAAAAT  
 CGGGTCACTCCACCCGAATATTGCGCTTTTCAGACCGGCTTAAGAAACGGCGCACACGAGACTATATCCACACCTGGCTCGAGGGTCT  
 CTACGCCACGGAATCTCGCTGATTGCTAGCACAGCAGTCTGAGATCAAAGTGAAGGGCGCAACGAGGCTGGGGGAGGGGCGCCGCCA  
 TTGCCAGGCTTGTAGGTAACAAGCAGCAGGGAAGCTGCAACTGGGTGGAGCCCACACAGCTCAAGGAGGCCTGCCTGCCTGTGT  
 AGGCTCCACCTCTGGGGCAGGGCACAGACAACAAAAAGACAGCAGTAACCTCTGCAGACTTAAGTGTCCCTGTCTGACAGCTTTGAAGA  
 GAGCAGTGGTCTCCAGCAGCAGCTGGAGATCTGAGAACGGCAGACTGCCTCCTCAAGTGGGTCCCTGACCCCTGACCCCGAGCAG  
 CCTAAGTGGGAGGCACCCCGCAGCAGGGGCACACTGACACCTCACAGGCAGGGTATTCCAACAGACCTGCAGCTGAGGGTCTGTCTGT  
 TAGAAGGAAACTAACAACAGAAAGGACATCTACACCGAAAACCCATCTGTACATCACCATCATCAAAGACCAAAGTATGATAAAACCAAAA  
 GATGGGGAAAAACAGAACAAGAAACTGGAAGCTTAAACCGCAGAGCGCCTCTCCTCCTCAAAGGAACGCAGTTCCTCACCAGCAACA  
 GAACAAAGCTGGATGGAGAATGATTTGATGAGCTGAGAGAAGGAGCTTCAGACGATCAAATTAATCTGAGCTACGGGAGGACATTCAAAC  
 CAAAGGCAAGAAAGTTGAAAACTTTGAAGAAATTTAGAAGAATGTATAACTAGAATAACCAATACAGAGAAGTGTCTAAAGAGCTGATGGAG  
 CTGAAAACCAAGGCTCGAGAACTACGTGAAGAATGCAGAAGCCTCAGGAGCCGATGCGATCAACTGGAAGAAAGGGTATCAGCAATGGAAG  
 ATGAAATGAATGAATGAAGCGAGAAGGGAAGTTTGTAGAAAAAAGAATAAAAAGAATGAGCAAAGCCTCAAAGAAATATGGGACTATGTGA  
 AAAGACCAATCTACGTCTGATTGTTGACTGAAAGTGTGTGGAGAATGGAACCAAGTTGGAAAACACTCTGCAGGATATATCCAGGAGA  
 ACTTCCCAATCTAGCAAGGCAGGCCAACGTTTCAAGTTCAGGAAATACAGAGAAGCCACAAAGATACTCCTCGAGAAGAGCAACTCCAAGA  
 CACATAATGTCAGATTCAACAAAGTTGAAATGAAGGAAAAATGTTAAGGGCAGCCAGAGAAAAGTCCGGTTACCCCTCAAAGGAAAGCC  
 CATCAGACTAACAGCGGATCTCTCGGCAGAACCCACAAGCCAGAAGAGACTGGGGGCCAATATTCAACATTTCTTAAGAAAAAGAAATTTCA  
 ACCCAGAATTTATATCCAGCCAACTAAGCTTCATAAGTGAAGGAGAATAAAATACTTTATAGACAAGCAAATGTTGAGAGATTTTGTACCA  
 CCAGGCTGCCCTAAAAGAGCTCCTGAAGGAAGCGCTAAACATGGAAGGAACAACCCGGTACCAGCCGCTGCAAAATCATGCCAAATGTAA  
 AGACCATCAAGACTAGGAAGAACTGCATCAACTAATGAGCAAAATCACCAGCTAACATCATAATGACAGGATCAACTTCACACATAACAAAT  
 AACTTTAAATATAATGGACTAAATTTGCAATTAAGAGACACAGACTGGCAAGTTGGATAAAGAGTCAAGACCCATCAGTGTGCTGTATTGAG  
 AAACCATCTCAGTGCAGAGACACATAGGCTCAAATAAAGGATGGAGGAAGATCTACCAAGCAATGAAAAACAAAAAGGCAGGG  
 GTTGCAATCCTAGTCTGTGATAAACAGACTTTAAACCAACAAGATGTTCAAAAGAGACAAGAAGGCCATTACATAATGGTAAAGGGATCAATTC  
 AACAAGAGGAGTAACTATCCTAAATTTATGCACCCAAATACAGGAGCACCCAGATTATAAAGCAAGTCTCAGTGACCTACAAGAGACTT  
 AGACTCCACACATTAATAATGGGAGACTTTAACACCCACTGTCAACATTAGACAGATCAACGAGACAGAAAGTCAACAAGGATACCCAGGA  
 ATTGAACTAGCTCTGCACCAAGCAGACCTAATAGACATCTACAGAATCTCCACCCCAAATCAACAGAAATATACATTTTTTTCAGCACAC  
 CACACCTATTCAAATTTGACCACATAGTTGGAAGTAAAGCTCTCCTCAGCAATGTAAGAAACAGAAATATAACAACTATCTCTCAGACCA  
 CAGTGAATCAAAGTAACTCAGGATTAAGAATCTCACTCAAAGCCGCTCAACTACATGGAAGTGAACAACCTGCTCCTGAATGACTACTG  
 GGTACATAACGAAATGAAGGCAGAAATAAAGATGTTCTTTGAAACCAACAGACTGAAAGAGACACACACATACCAAGATCTCTGGGACGATCAA  
 AGCAGTGTGTAGAGGAAATTTATAGCACTAAATGCCTACAAGAGAAAGCAGGAAAGATCCAAAATGACACCTAACATCACAATTAAGAA  
 CTAGAAAAGCAAGAGCAACACATTTAAAAGCTAGCAGAAGGCAAGAAATAACTAAAATCAGAGCAGAACTGAAGGAAATAGAGACAAAA  
 ACCCTTCAAATAATCAATGAATCCAGGAGCTGGTTTTTGAAGGATCAACAAAATGATAGACCGCTAGCAAGACTAATAAGAAAAAAGAG  
 AGAAGAATCAATAGACACAATAAAAAATGATAAGGGGATATCACCACCGATCCACAGAAATACAACTACCATCAGAGAATACTACAACAC  
 CTCTACGCAATAAAGTAAAACTAGAAGAAATGGATACATTCCTGCACATACACTCTCCAAAGACTAAACAGGAAAGAAATGAAATCTC  
 TGAATCGACCAATAACAGGCTCTGAAATTTGGCAATAATCAATAGTTTACCAACCAAAAGAGTCCAGGACCATGGAATTCACAGCCGAAT  
 CTACCAGAGTACAAGGAGAACTGGTACCATTCTTCTGAACTATTCCAATCAATAGAAAAAGAGGGAATCCTCCCTAACTCATTTTATGAG  
 GCCAGCATCTGTGATACCAAGCCGGGCGAGACACAACAAAAAGAGAATTTAGACCAATATCCTTGATGAACATTGATGAAAAATCC  
 TCAATAAAATCTGGCAACCGAATCCAGCAGACATCAAAAAGCTTATCCACATGATCAAGTGGGCTTCATCCCTGGGATGCAAGGCTGGT  
 TCAATATACGCAATCAATAATGTAATCCAGCATATAACAGAGCCAAAGACAAAAACCATGATTATCTCAATAGATGCAGAAAAAGCCTTTG

ACAAAATTCACAACCCTTCATGCTAAAACTCTCAATAATTAGGTATTGATGGGACGTATTTCAAATAATAAGAGCTATCTATGACAAAACCA  
CAGCCAATATCATACTGAATGGGCAAAAACCTGGAAGCATTCCCTTTGAAAACCGGCACAAGACAGGGATGCCCTCTCTACCCTCCATTCA  
ACATAGTGTGGAAAGTTCTGGCCAGGGCAATCAGGCAGGAGAAGGAAATAAAGGGTATTCAATTAGGAAAAGAGGAAATGTCCTG  
TTTGCAGACGACATGATTGTTTATCTAGAAAACCCATCGTCTCAGCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGTCTCAGGAT  
ACAAAATCAATGTACAAAAATACAAGCATTCTTATACACCAACAACAGACAAAACAGAGGCCAAATCATGGGTGAACCTCCATTACAATTGC  
TTCAAAGAGAATAAAAACCTAGGAATCCAACCTACAAGGGATGTGAAGGACCTCTTCAAGGAGAACTACAAACCACTGCTCAAGGAAATAAAA  
GAGGAGACAAAACAAATGGAAGAATCCATGCTCATGGGTAGGAAGATCAATATCGTGAATGGCCATACTGCCAAGGTAATTTACAGAT  
TCAATGCCATCCCATCAAGCTACCAATGACTTTCTCACAGAATTGAAAAAACACTTTAAAGTTTCATATGAAACAAAAAGAGCCCGCATT  
GCCAAGTCAATCCTAAGCAAAAAGCAAAAGCTGGAGGCATCACACTACCTGACTTCAAACATACTACAAGGCTACAGTAACCAAAACAGCA  
TGGTACTGGTACCAAAACAGAGATATAGATCAATGGAACAGAACAGGCCCTCAGAAATAATGCCGCATATCTACAATATCTGATCTTTGACAA  
ACCTGAGAAAAACAAGCAATGGGAAAAGGATTCCCTATTTAATAAATGGTGTGGGAAAACCTGGCTAGCCATATGTAGAAAAGCTGAAACTGGA  
TCCCTTCTTACACCTTATACAAAAATCAATTCAGATGGATTAAGATTAAACGTTAAACCTAAAACCATAAAAACCTTAGAAGAAAACCTAGG  
CATTACCATTGAGACATAGGCGTGGGCAAGGACTTCATGTCCAAAACACCAAAAGCAATGGCAACAAAAGACAAAATTGACAAATGGGATCT  
AATTAACATAAAGAGCTTCTGCACAGCAAAGAACTACCATCAGAGTGAACAGGCAACCTACAACATGGGAGAAAAATTTTGC AACCTACTCA  
TCTGACAAAGGGCTAATATCCAGAATCTACAATGAACTCAACAATTTACAAGAAAAAAACAAACAACCCCATAAAAAGTGGCGAAGGACA  
TGAACAGACACTTCTAAAAGAAGACATTTATGCAGCCAAAAACACATGAAGAAATGCTCATCATCACTGGCCATCAGAGAAATGCAAATCAA  
AACCACTATGAGATATCATCTCACACCAGTTAGAATGGCAATCATTAAAAAGTCAGGAACAACAGGTGCTGGAGAGGATGCGGAGAAATAGG  
AACACTTTTACACTGTTGGTGGGACTGTAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGATTCTCAGGGATCTAGAACTAGAAATACC  
ATTTGACCCAGCCATCCATTACTGGGTATATACCCAAATGAGTATAAATCATGCTGCTATAAAGACACATGCACACGTATGTTATTGCGGCACT  
ATTACAATAGCAAAGACTTGGAAACAACCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACCCATGGAATACTATG  
CAGCCATAAAAAATGATGAGTTTCATATCCTTTGTAGGGACATGGATGAAATGGAAACCATCATTCTCAGTAACTATCGCAAGAACAAAAAAC  
AAACACCGCATATTTCTACTCATAGGTGGGAATTGACAATGAGATCACATGGACACAGGAAGGGGAATATCACACTCTGGGGACTGTGGTG  
GGGTGCGGGGAGGGGGGAGGATAGCATTGGGAGATATACCTAATGCTAGATGACACAATTAGTGGGTGCAGCGCACCATGACATGT  
ATACATATGTAACCTGCACAATGTGCACATGTACCCTAAAACCTTAGAGTATAAT

**Supplementary Sequence 3.** DNA sequences of pU6-pegRNAs, lentiCRISPR v2 plasmid, pCMV-PE2 plasmid, pCMV-BEs (BE2/BE3/BE4-Gam/AncBE4max/ABE8e) plasmids used for insertion sources analysis.

### 3.1.1 pU6-pegRNA (for MYC +2-4AAAdel) (497 bp)

| Features        | Start | end |
|-----------------|-------|-----|
| pU6             | 82    | 330 |
| pegRNA          | 331   | 455 |
| Spacer          | 331   | 350 |
| RT (+2-4AAAdel) | 427   | 442 |
| PBS             | 443   | 455 |

Gacgtcgtagctgtacaaaaagcaggcttaaggaaccaattcagtcgactggatccggtaccaaggtcgggcaggaagagggcctatttccatgattcctcatattgcatatagatacaaggctgtagagagataaattgactgtaaacacaaagatattagtagcaaaatcgtgacgtagaagtaataattctggtagttgcagtttaaaatattgtttaaaatggactatcatatgctaccgtaactgaaagtattcgtattctggcttataatcttggaaaggacgaaa**CACC**GACTGTCCAAAGGGGGTGAA**GTTTTAGAG**CTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGCCACCGAGTCG**GTGCA**TAAAGGGAGCACCCACCCCTTTGGACtttttaagctggccgctcgaggtaacctctcatatg

### 3.1.2 pU6-pegRNA (for MYC +5GtoC) (496 bp)

| Features   | Start | end |
|------------|-------|-----|
| pU6        | 82    | 330 |
| pegRNA     | 331   | 455 |
| Spacer     | 331   | 350 |
| RT (5GtoC) | 427   | 441 |
| PBS        | 442   | 454 |

Gacgtcgtagctgtacaaaaagcaggcttaaggaaccaattcagtcgactggatccggtaccaaggtcgggcaggaagagggcctatttccatgattcctcatattgcatatagatacaaggctgttagagagataaattgactgtaaacacaaagatattagtagcaaaatcgtgacgtagaagtaataattctggtagttgcagttttaaaatattgtttaaaatggactatcatatgctaccgtaactgaaagtattcgtattctggcttataatcttggaaaggacgaaa**CACC**GACTGTCCAAAGGGGGTGAA**GTTTTAGAG**CTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGCCACCGAGTCG**GTGCA**AGGGAGCACCGTTTCACCCCTTTGGACtttttaagctggccgctcgaggtaacctctcatatg

### 3.1.3 pU6-pegRNA (for FANCF +5GtoT) (500 bp)

| Features   | Start | end |
|------------|-------|-----|
| pU6        | 82    | 330 |
| pegRNA     | 331   | 455 |
| Spacer     | 331   | 350 |
| RT (5GtoT) | 427   | 443 |
| PBS        | 444   | 458 |

Gacgtcgtagctgtacaaaaagcaggcttaaggaaccaattcagtcgactggatccggtaccaaggtcgggcaggaagagggcctatttccatgattcctcatattgcatatagatacaaggctgttagagagataaattgactgtaaacacaaagatattagtagcaaaatcgtgacgtagaagtaataattctggtagttgcagttttaaaatattgtttaaaatggactatcatatgctaccgtaactgaaagtattcgtattctggcttataatcttggaaaggacgaaa**CACC**GGATCCCTTCTGCAGCACCGTTT**AGAG**CTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGCCACCGAGTCG**GTGCA**AGAAAGCGGATCAAGGT**GCTGCAGAAGGGATT**tttttaagctggccgctcgaggtaacctctcatatg

## 3.2 lentiCRISPR v2 plasmid

can be found in <https://www.addgene.org/52961/>

## 3.3 pCMV-PE2 plasmid


can be found in <https://www.addgene.org/132775/>

## 3.4 pCMV-BEs plasmids

pCMV-BE2 (Addgene plasmid #73020), pCMV-BE3 (Addgene plasmid #73021), pCMV-BE4-Gam (Addgene plasmid #100806), pCMV-AncBE4max (Addgene plasmid #112094) and pCMV-ABE8e (Addgene plasmid #138489) can be found in <https://www.addgene.org/>.



**Supplementary Sequence 5.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the PE3 (MYC +2-4AAA del) editing site in HEK293T cells expressing L1-ORFeus.



**Example #1 (edits deleted)**

>M00851:457:000000000-CK7JC:1:2106:17702:11039 (pair end)

GCTGGTTCACTAAGTGCCTCCGAGATAGCAATATCACGGGTAGCCAAACGCTATGTCCTGATAGCGGTCCGCCGCTTTACTTGTACAGCTCGTCCATGC  
 CGAGAGTGATCCCGCGCGGGTACGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTGCTCAGGGCGGACTGGGTGCTCAGGTAGT  
 GGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGTTAGTGGTCGGCCAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCT  
 TTATTCACCAAGACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAG

Sequence color annotation: MYC locus Microhomology L1-ORFeus insertions (+): GFP-CT GFP-NT


**Example #2**

>M00851:457:000000000-CK7JC:1:1101:17292:2963 (pair end)

GCTGGTTCACTAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAGGGGGTGGGTTGCTCCCTTATTCCGCCAACACATCGAGGACGGCAGCGTGCA  
 GCTGGCCGACCACTACCAGCAGAACACCCCATCGGCGACGCTTTAGGGGATAGCTCTGCAAGGGGAGAG

Sequence color annotation: MYC locus pegRNA editing site Microhomology L1-ORFeus insertions (-): GFP-NT GFP-CT

**Supplementary Sequence 6.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the MYC CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.



**Example #1**

>M00851:382:000000000-CF5PB:1:2103:18157:2519 (pair end)

GATCGCGGGTGTGGTTCATAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAGGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCCAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTTGATGCGTTCCTTCTGCTTGTCCGCCATGATATAGACGTTGTGGCTCCCTTTATTCCCCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTCTC

Sequence color annotation: MYC locus **Microhomology** L1-ORFeus insertions (+): GFP-CT GFP-NT

**Example #2**

>M00701:747:000000000-CFM9G:1:2110:14086:2427 (pair end)

CAGCTGGTTCATAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAGGCATCAAGGTGAACCTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGACCTGGCTGACCACTACCAGCAGAACACCCCATCGGCGACGGCCCGTGTCTGCTGCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGGGTGTCCCTTTATTCCCCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTC

Sequence color annotation: MYC locus **Microhomology** L1-ORFeus insertions (-): GFP-NT GFP-CT

**Example #3**


>M00701:747:000000000-CFM9G:1:1104:22072:21267 (pair end)

CAGCTGGTTCATAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAGGGGGTGTCTGCTGGGAGTGGTCCGGCCAGCTGCACGCTGCCGCTCTCCCTTTATTCCCCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTC

Sequence color annotation: MYC locus **Microhomology** L1-ORFeus insertions (+): GFP-CT GFP-NT



**Supplementary Sequence 7.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the RAG1 CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.



**Example #1**

>M00701:747:000000000-CFM9G:1:1105:8807:6910 (pair end)

ACGCGCTGCGTAAGATACATCAGTGGGATATTGATATTGGTCTTAATATGACTTGTTCATTGTTCTCAGGTACCTCAGCCAGCATGGCAGCCTCTT  
TCCCACC**CACTGTGCGTTTTATTCTGCTTTTTATTGCCGATCCCTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGG**  
**GAGCGCGATACCGTAAAGCAGGAGGAAGCGGTGAGCCATTCGCCGCAAGCTCTCAGCAATATCACGGGTAGCCAACGCTATGCTCTGATAG**  
**CGGTGCGCGCTTTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGCGGCGGTACGAACTCCAGCAGGACCATGTGATCGCGCTGCTCGTT**  
**GAGGTCTTGTCTCAGGCGGACTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTGCCGATGGGGGTGTTCTGCTGGTAGTGG**  
**TCGGCCAGCTGCACGCTGCCCTCGATGTTGTGGCGGATCTTGAAGTTCACTCAGTTCTGCCCCAGATGAAATTCAGCACCCACATATTAATTTT**  
CAGAATGAAATTTAAGCTGTTCCGGGTGAGATCCT

Sequence color annotation: RAG1 locus **Microhomology L1-ORFeus insertions (+):** GFP-NT GFP-CT

**Example #2**

>M00701:747:000000000-CFM9G:1:1113:12595:14133 (pair end)

ACGCGCTGCGTAAGATACATCAGTGGGATATTGATATTGGTCTTAATATGACTTGTTCATTGTTCTCAGGTACCTCAGCCAGCATGGCAGCCTCTT  
TCCCACC**CATCTCTGGG**GCACAAGCTGGAGTACAACACAGCCACAACGCTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAAC  
**TTCAAGATCCGCCACAACATCGAGGACGCGCAGCTGAGCTGGCCGACCCTACCAGCAGAACACCCCATCGGCGACGGCCCGTCTGCTGCTGCC**  
**CGACAACCACTACTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGTTCTGACCGCCGCCG**  
**GGATCACTCTCGGCATGGACT**TCAGTTCTGCCCCAGATGAAATTCAGCACCCACATATTAATTTTCAAGAATGAAATTTAAGCTGTTCCGGGTGAGA  
TCCTCTG

Sequence color annotation: RAG1 locus **Microhomology L1-ORFeus insertions (-):** GFP-NT GFP-CT

**Example #3**

>M00701:748:000000000-CFM62:1:2101:12456:25523 (pair end)


ACGCGCTGCGTAAGATACATCAGTGGGATATTGATATTGGTCTTAATATGACTTGTTCATTGTTCTCAGGTACCTCAGCCAGCATGGCAGCCTCTT  
TCCCACC**CA**GCAGGACCATGTGATCGCGTTCTCGTTGGGGTCTTGTCTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTGGGCAGCAGCACG  
**GGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTGGCCAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTACCTTGATG**  
**CCGTTCTTCTGCTTGTGGCCATGATATAGACGTTGTGGCTGTTGTAGTTGACTCCAGCTTGTGCCCCAGGATGTTGGGACTCAGTTCTGCCCCAG**  
ATGAAATTCAGCACCCACATATTAATTTTCAAGAATGAAATTTAAGCTGTTCCGGGTGAGATCCTCTGA

**Example #4**

>M01559:236:000000000-CHDLT:1:2101:16442:20380 (pair end)

ACGCGCTGCGTAAGATACATCAGTGGGATATTGATATTGGTCTTAATATGACTTGTTCATTGTTCTCAGGTACCTCAGCCAGCATGGCAGCCTCTT  
TCCCACC**CA**TGTGATCGCGCTTCTCGTTGGGGTCTTGTCTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTGGGCAGCAGCACGGGGCCGCTCG  
**CCGATGGGGGTGTTCTGCTGGTAGTGGTGGCCAGCTGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTACCTTGATGCCGTTCTTCT**  
**GCTTGTGGCCATGATATAGACGTTGTGGGACTCAGTTCTGCCCCAGATGAAATTCAGCACCCACATATTAATTTTCAAGAATGAAATTTAAGCTG**  
TTCGGGTGAGATCCT

**Supplementary Sequence 8.** L1-ORFeus insertion bridging the intron of GFP obtained by amplicon sequencing at the CCR5 CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus.




**Example #1**

>M01559:337:000000000-JBGB2:1:2108:10959:9836 (pair end)

ATGATGTACCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCTCATTTCATACATCAAGGTGAACCTCAAG  
 ATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTGGCCGACCACTACCAGCAGAACACCCCATCGGGCAGCGCCCGTGTCTGCTGCCCGAC  
 AACCACTACCTGAGCACCAGTATCAATTCTGGAAGAATTTCCAGACATTAAGATAGTCATCTTGGGGCTGGTCTG

Sequence color annotation: CCR5 locus **Microhomology** L1-ORFeus insertions (-): GFP-NT GFP-CT

**Supplementary Sequence 9.** L1-ORFeus insertions bridging the intron of GFP obtained by amplicon sequencing at the MYC CRISPR/Cas9 target site in HeLa cells expressing L1-ORFeus.



Sequence color annotation: MYC locus **Microhomology L1-ORFeus insertions (+)**: GFP-CT GFP-NT

**Example #1**

>M00701:936:000000000-JT8MN:1:2109:15161:26467 (pair end)

TGCTGCTGGTTACTAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAAGGGGGT **CGGCGGCGGTACGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTCTGCTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCACGGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCCAGCTGCACGCTGCCGCTCCGATGTTGTGGCGGATCTTGAAGTTCACCTTGATGCAGTTCTTCTGCTTGTCCGATGATAGACGTTGTGGCTGTTGTAGTTGTACTCCAGCTTGCCCTTGAAAGGGTGCTCCCTTATTCCCCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTC**

**Example #2**

>M00701:936:000000000-JT8MN:1:1105:6364:9728 (pair end)


TGCTGCTGGTTACTAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAA **GGGACTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCAGCGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCCAGCTGCACGCTGCCGCTCCGATGTTGTGAAGGGTGCTCCCTTATTCCC**CCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTC

**Example #3**

>M00701:936:000000000-JT8MN:1:1104:11116:4812 (pair end)

GATCGCGCGGTGCTGGTTACTAAGTGCCTCCGAGATAGCAGGGGACTGTCCAAA **GGTAGTGGTCGGCCAGCTGCACGCTGCCGCTCCGATGTTGTGGCGGATCTTGAAGTTCACCTTGATGCCGTTCTTCTGCTTGTGGCCATGATATAGACGTTGTGGCTGTTGTAGTTGACTCCAGCTTGTGCCCAAGGATGTTGCCGCTCCTTGAAGTCGATGCCCTTCACTCGATGCGGTTACCAGGGTGTGCGCCCTCGAACTTCACTCGTTATT**CCCCACCAAGACCACCCAGCCGCTTTAGGGGATAGCTCTGCAAGGGGAGAGCTC

**Supplementary Sequence 10.** L1-ORFeus insertional sequence obtained by amplicon sequencing at the CCR5 CRISPR/Cas9 target site in HEK293T cells expressing L1-RTm.




**Example #1**

>M01559:337:000000000-JBGB2:1:1110:23520:10454 (pair end)

GATCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACCTGCAGCTCTCATTTCCATATAAAGATGAACCCATAGTG  
 AGCTGAGAGCTCCAGCTGGCCCTCAGATAAAGTACACACCCAGCTTCCA TAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAGA  
 TAGTCATCTTGGGGCTGGTCTGAGCA

Sequence color annotation: CCR5 locus **Microhomology** L1-ORFeus insertions (-)

The alignment of example #1 read sequence with the L1-ORFeus vector showed this insertion is in the intron region.







**Example #7**

>M00701:791:000000000-CK823:1:1108:15367:23104

GCAATAACAAGTTAACACAAaaaaaaaaaaaaaaaaaaaaaaaaataaggggggggggggggacttaacaaaatcacaccaacg  
tattttattaacaacatgcctaagtggaagcttgctgccattgtttcaaatcttgcagtttcttcttttcagatattattta  
ctccccacctgctgccagtcacgaccaaattgtataaactgtagactgctccaactctctgccttttaagctgaaat

**L1-ORFeus insertion at chr9:32843666 strand (+)**

```

00000001 GCAATAACAAGTTAACACAAaaaaaaaaaaaaaaaaaaaaaaaaataaggg 00000050
>>>>>>> |||||  >>>>>>>
32843632 catgccttttagctcctaagaaattgatttaag ttaaaaaa aaaaataaggt 32843681

00000051 gggggggggggaggacttaacaaaatcacaccaacgtattttattaacaa 00000100
>>>>>>> |||||  >>>>>>>
32843682 ggtgggggtggaggacttaaccaaatacacaccaacgtattttattaacaa 32843731

00000101 catgcctaagtggaagcttgctgccattgtttcaaatcttgcagttt 00000150
>>>>>>> |||||  >>>>>>>
32843732 catgcctaagtggaagcttgctgccacttgattcaaatgcctgcagttt 32843781

00000151 cttcttttcagatattattactccccacctgctgccagtcacgaccaa 00000200
>>>>>>> |||||  >>>>>>>
32843782 cttcttttcagatattattactctccacctgctgccagtcacgcacaa 32843831

00000201 attgtataaactgtagactgctccaactctctgccttttaagctgaaat 00000250
>>>>>>> |||||  >>>>>>>
32843832 attgtataaactgtagactgctccaactctctgccttttaagctgaaat 32843881

```

**Example #8**

>M00701:791:000000000-CK823:1:1102:5950:22540

GCAATAACAAGTTAACACAAaaaaaaaaaaaaaaaaaaaaaaaaagtgaaaactaatcttttcattttttaaattcattaattca  
ttcagcaagtatttttgcacatccaagcatatttgatcacgtgcttggcattcttttaggtcagatattctcagcgttgataac  
cagccgggcccgcgaccacgcgtgccctatagctagcagactcagatcggaaggcgggtcagcaggaatgccgat

**L1-ORFeus insertion at chr11:8542738 strand (+)**

```

00000001 GCAATAACAAGTTAACACAAaaaaaaaaaaaaaaaaaaaaaaaaagtgaaa 00000050
<<<<<<<< |||||  <<<<<<<<
8542773 gccactgcactccagcctgggtgacagagtgct ttaaaaaa aaaagtgcaa 8542724

00000051 actaaatcttttcatttttttaaattcattaattcattcagcaagtattt 00000100
<<<<<<<< |||||  <<<<<<<<
8542723 actaaatcttttcatttttttaaattcattaattcattcagcaagtattt 8542674


00000101 ttgcatcatccaagcatatttgatcacgtgcttggcattcttttaggtca 00000150
<<<<<<<< |||||  <<<<<<<<
8542673 ttgcatcatccaagcatatttgatcacgtgcttggcattcttttaggtca 8542624

00000151 gtatttctcagcgttgg 0000167
<<<<<<<< |||||  <<<<<<<<
8542623 gtatttctcagcgttgg 8542607

```

**Supplementary Sequence 12.** Example L1Hs sequences obtained by amplicon sequencing at the MYC/RAG1 CRISPR/Cas9 target site in HEK293T cells.

Trinucleotide in 3'UTR feature within indicated endogenous L1 family



**Example #1** (at MYC CRISPR/Cas9 target site in HEK293T cells expressing L1-RTm)

```
> M00851:382:000000000-CF5PB:1:1104:23807:16329
CGATCATGATCGGCTGGTTCACTAAGTGCCTCCGAGATAGCAGGGGACTGTCAAAGGGGGGTAGGAGGAGGGGGGAGGG
ATAGCATTGGGAGATATACCTAATGCTAGATGACACAATTAGTGGGTGCAGCGCACCAGCATGGCACATGTATACATATGTAAC
AACCTGCACAATGTGCACATGTACCCTAAAACCTTAGAGTATAATAAAATAAGGGGTGCTCCCTTTATCCCCACCAAGACCAC
CCAGCCGCTTAGGGGATAGCTCTGCAAGGGAGAG
```

Sequence color annotation: MYC locus L1Hs sequences (+) Trinucleotide in 3'UTR PolyA tail Microhomology

**Example #2** (at RAG1 CRISPR/Cas9 target site in HEK293T cells expressing L1-ORFeus)

```
> M00701:748:000000000-CFM62:1:2104:18741:6169
ACGCGCTGCGTAAGATACATCAGTGGGATATTGATATTGGTCTTAATATGACTTGTTCATTGTTCTCAGGTACCTCAGCCAGCA
TGGCAGCCTCTTCCACCCACTTTTTTTTTTATTATACTCTAAGTTTTAGGGTACATGTGCACATTGTGCAGGTTAGTTACATATG
TATACATGTGCCATGCTGGTGCACCTGCACCCACTAATGTTGTCATCTAGCATTAGGTATATATGGGGCTCAGTGCTGCCCCAGATG
AAATTCAGCACCCACATATTAATTTTTCAGAATGGAAATTAAGCTGTTCCGGGTGAGATCCT
```

Reverse complementary sequence:


```
AGGATCTCACCCGGAACAGCTTAAATTTCCATTCTGAAAATTAATATGTGGGTGCTGAATTCATCTGGGGCAGCACTGAGCCC
CATATATACCTAATGCTAGATGACACAATTAGTGGGTGCAGTGCACCAGCATGGCACATGTATACATATGTAACCTGCACA
ATGTGCACATGTACCCTAAAACCTTAGAGTATAATAAAAAAAAAAGTGGGTGGGAAAGAGGCTGCCATGCTGGCTGAGGTACCT
GAGAACAAATGAAAACAAGTCATATTAAGACCAATATCAATATCCCACTGATGTATCTTACGCAGCCGCT
```

Sequence color annotation: RAG1 locus L1Hs sequences (-) Trinucleotide in 3'UTR PolyA tail



**Supplementary Sequence 13.** DNA sequences of pCEP4 L1RP, pCEP4 L1RP-ENm (H230A) (L1RP-ENm), and pCEP4 L1RP-RTm (D702Y) (L1RP-RTm) plasmids used in this study.

**13.1 pCEP4 L1RP (1-17897bp)** can be found in <https://www.addgene.org/131392/>



| Features     | Regions (bp) |
|--------------|--------------|
| CMV promoter | 30-605       |
| L1 5'UTR     | 689-1594     |
| ORF1 (L1RP)  | 1595-2611    |
| ORF2 (L1RP)  | 2675-6502    |
| GFP-CT       | 6681-7065    |
| HBG-intron   | 7066-7965    |
| GFP-NT       | 7966-8499    |

GTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGTCCCGGTTACGTAACCTACGGT  
AAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTC  
ATTGACGTCAATGGTGGAGTATTACCGTAAACTGCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCTATTGACGTCAA  
TGACGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT  
ACCATGGTGATGCGGTTTTGACAGTACCCAATGGGCGTGGATAGCGGTTTTGACTCACGGGGATTCCAAGTCCACCCCATGACGTCAA  
TGGGAGTTTTGTTTGGCACAAAATCAACGGGACTTTCAAAATGTCGTAATAACCCCGCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC  
GGTGGGAGGTCTATATAAGCAGAGCTCGTTTGTAGTGAACCGTCAGATCTCTAGAAGCTGGGTACCAGCTGCTAGCAAAGCTTGGTACGGCCGC  
TCTAGCCCTGGAATGTGTTAAGACTGTAAGGTGGGGGGGAGGAGCCAAGATGGCCGAATAGGAACAGCTCCGGTCTACAGCTCCAGCG  
TGAGCGACGCAGAAGACGGTGTATTTCTGCATTTCCATCTGAGGTACCGGGTTCATCTCACTAGGGAGTGCCAGACAGTGGGCGCAGGCCAG  
TGTGTGTGCGCACCGTGTGCGGAGCCGAAGCAGGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTGAGGGAGTTCCTTTCCGAGT  
CAAAAGAAAGGGGTGACGGAGCGACCTTGAAAATCGGGTCACTCCACCCGAATATTGCGCTTTTTCAGACCGGCTTAAGAAAACGGCCGACCA  
CGAGACTATATCCCGCACCTGGCTCGGAGGGTCTACGCCACGGAATCTCGCTGATTGCTAGCACAGCAGTCTGAGATCAAACCTGCAAGG  
CGGCAACGAGGCTGGGGGAGGGGCGCCGCCATTGCCAGGCTTGTCTAGGTAACAAAGCAGCAGGGAAGCTCGAACTGGGTGGAGCC  
CACCACAGCTCAAGGAGGCCCTGCCTGCCTCTGTAGGCTCCACCTCTGGGGGAGGGCACAGACAACAAAAAGACAGCAGTAACCTCTGC  
AGACTTAAGTGTCCCTGTCTGACAGCTTTGAAGAGAGCAGTGGTTCTCCAGCAGCAGCTGGAGATCTGAGAACGGGAGACTGCCTCCT  
CAAGTGGTCCCTGACCCCTGACCCCGAGCAGCTAAGTGGGAGCCACCCCGCAGGGGACACTGACACCTCACACGGCAGGGTA  
TTCCAACAGACTGCAGCTGAGGGTCTGTCTGTTAGAAGGAAAATGCAACCAACGAAAAGGACATCTACACCGAAAACCCATCTGTACATCAC  
CATCATCAAAGACAAAAGTAGATAAAACCAAAAGATGGGGAAAAACAGAACAAGAAAAGTGGAAAAGTCTAAAACGCAGAGCGCTCTCCT  
CCTCCAAAGGAACGCAGTTCCTCACCAGCAACAGAACAAGCTGGATGGAGAATGATTTTGTAGCTGAGAGAAGAAGGCTTCAGACGATC  
AAATTAATCTGAGCTACGGGAGGACATTCAAACCAAGGCAAGAAGTTGAAAAGTCTTGAAGAAAATTTAGAAGAATGTATAACTAGAATAACCA  
ATACAGAGAAGTGCTTAAAGGAGCTGATGGAGCTGAAAACCAAGGCTCGAGAAGTACGTAAGAATGCAGAAGCCTCAGGAGCCGATGCGA  
TCAACTGGAAGAAAAGGATCAGCAATGGAAGATGAAATGAATGAAATGAAGCAGAGAAGGGAAGTTTGAAGAAAAGAAATAAAAAGAAATGA  
GCAAGGCTCCAAAGAAATGGGACTATGTAAAAGACCAACTTACGCTGATTGGTGTACCTGAAAGTGAATGGGAAATGGAACCAAGTT  
GGAAAACACTCTGCAGGATATTCCAGGAGAAGTTCCTCAATCTAGCAAGGCAGGCCAACGTTTTCAGATTGAGGAAATCAGAGAAGCCAC  
AAAGATACTCCTCGAGAAGGCAACTCAAGACACATAATGTGAGATTACCAAGTTGAAATGAAGGAAAAATGTTAAGGGCAGCCAGAG  
AGAAAGGTGGGTTACCCCTCAAAGGAAAAGCCATCAGACTAACAGCGGATCTCTCGCAGAAACCTACAAGCCAGAAGAGAGTGGGGC  
CAATATTCACATTCTTAAAGAAAAGAATTTCAACCCAGAATTCATATCCAGCCAACTAAGCTTCATAAGTGAAGGAGAATAAAATCTTTAT  
AGACAAGCAATGTTGAGAGATTTTGTACCACAGGCTGCCCCAAAAGAGCTCCTGAAGGAAGCGCTAAACATGGAAGGAACACCCGGT  
ACACGCCCTGCAAAATCATGCCAAAATGTAAAGACCATCAAGACTTAGGAAGAACTGCACCACTAATGACCACTAATGACCAAACTCCTGATACATCA  
TAATGACAGGATCAACTTCACACATAACAATTAACCTTTAAATATAAATGGACTAAATCTGCAATTAAGGACACAGACTGGCAAGTTGGATAA  
AGAGTCAAGACCCATCAGTGTGCTGTATTGAGGAAACCCATCTCACGTGCAGAGACACATAGGCTCAAATAAAAGGATGGAGGAAGATCT  
ACCAAGCCAATGAAAACAAAAAGGCAAGGGTTCGAATCCTAGTCTCTGATAAAACAGACTTTAAACCAACAAAGATCAAAGAGACAAAAG  
AAGGCCATTACATAATGGTAAAGGGATCAATCAACAAGAGGAGCTAATCTCAATATTTATGCACCAATACAGGAGCACCCAGATTACATA  
AAGCAAGTCTCAGTACCTACAAGAGACTTAGACTCCACACATTAATAATGGGAGACTTTAACACCCCACTGTCAACATTAGACAGATCAA  
CGAGACAGAAAAGTCAACAAGGATACCCAGGAATGAACCTAGCTCTGCACCAAGCAGACTAATAGACATCTACAGAATCTCCACCCCAAT  
CAACAGAATATACGTTTTTTCAGCACACACACACTATTCCAAAATGACCACATAGTTGGAAGCAAAGCTCTCCTCAGCAAATGTAAAAG  
AACAGAAATATAACAACTATCTCTCAGACACAGTGAATCAAAGTACAGCTCAGGATTAAGAATCTCACTCAAAGCCGCTCACTACATGG  
AACTGAACACCTGCTCCTGAATGACTACTGGGTACATAACGAATGAAGGCAGAAATAAGATGTTCTTTGAAACCAACGAGAACAAGAC  
ACCACATACCAGAATCTCTGGGACGCATTCAAAGCAGTATGTAGAGGGAAATTTATAGCACTAAATGCCTACAAGAGAAAAGCAGGAAAGATCC  
AAAATTGACACCTAACATCACAATTAAGAACTAGAAAAGCAAGAGCAACACATTCAAAAGCTAGCAGAAGGCAAGAAATAACTAAAATCA  
GAGCAGAACTGAAGGAATGAGAGACACAAAAACCCCTCAAAAATCAATGAACTCCAGGAGCTGGTTTTTTGAAAGGATCAACAGAAATGATA  
GACCCTAGCAAGACTAATAAGAAAAAAGAGAGAAGTCAAATAGACACAATAAAAAATGATAAAGGGATATCACCCAGTCCCACAGA  
AATACAACTACCATCAGAGAATACTACAACACCTCTACGCAATAAACTAGAAAATCTAGAAGAAATGGATACATCTCTCGACACATACACTCT  
CCCAAGACTAAACAGGAAGGATTTGAATCTCTGAATCGACCAATAACAGGCTCTGAAATGTGGCAATAATCAATAGTTTACCAACCAAAAAG  
AGTCCAGGACAGATGGATTACAGCCGAATTTACAGAGGTACAAGGAGGAACTGGTACCATTCTCTGAAACTATTCAATCAATAGAA  
AAAGAGGAAATCTCCCTAATCATTTTATGAGGCCAGCATCTGTATCAAAAAGCCGGCAGAGACACAACCAAAAAAGAGAATTTTGA  
CCAAATCCTTGATGAACATTGATGCAAAAATCCTCAATAAAATCAATGAACTCCAGGACATCAAAAAGCTTATCCACCATGATCA  
AGTGGGCTTCATCCCTGGGATGCAAGGCTGGTTCAATATACGCAATCAATAATGTAATCCAGCATATAACAGAGCCAAAGACAAAAACCCAC

ATGATTATCTCAATAGATGCGAAAAAGCCTTTGACAAAATCAACAACCCCTCATGCTAAAAACTCTCAATAAATAGGTATTGATGGGACGTAT  
TTCAAATAAAGAGCTATCTATGACAAAACCCACAGCCAATATCACTGAATGGGCAAAAACTGGAAGCATTCCCTTTGAAAACCGGCACAA  
GACAGGGGATGCCCTCTCTACCCGCTCTATTCAACATAGTGTGGAAGTTCTGGCCAGGGCAATCAGGCAGGAGAAGGAAATAAAGGGTATT  
CAATTAAGAAAAGGAAAGTCAATTTGCTGTTTGCAGATGATTGTTTATCTAGAAAACCCCATGCTCAGCCAAAATCTCCTTA  
AGCTGATAAGCAACTCAGGATACAAAATCAATGACAAAATCAACAAGCATTCTATACACCAACAGACAAAACAGAGAG  
CCAAATCATGGGTGAACCTCCATTACAATTGCTTCAAGAGAATAAAATACCTAGGAATCCAATTACAAGGGATGTGAAGGACCTCTCAAG  
GAGAACTACAACCCTGCTCAAGGAAATAAAGAGGAGACAAAATAAGGAAGAACATTCCATGCTCATGGGTAGGAAGAATCAATATCGT  
AAAATGGCCATACTGCCAAGGTAATTTACAGATTCAATGCCATCCCATCAAGCTACCAATGACTTTCTTACAGAAATTGAAAAAATCTTT  
AAAGTTCCATGGAACAAAAAGAGCCGATTGCCAAGTCAATCCTAAGCCAAAAGAACAAAGCTGGAGGCATCACACTACCTGACTTCAA  
ACTATACTACAAGGCTACAGTAACCAAAACAGCATGGTACTGGTACCAAAACAGAGATATAGATCAATGGAACAGAACAGAGCCCTCAGAAATA  
ATGCCCGCATATCTACAACCTATCTGATCTTTGACAAACCTGAGAAAAACAAGCAATGGGAAAGGATTCCCTATTTAAATAAATGGTCTGGGAAA  
ACTGGCTAGCCATATGTGAAAAGCTGAAACTGGATCCCTTCTTACACCTTATACAAAATCAATTCAAGATGGATTAAAGATTAAACGTTAAAC  
CTAAAACCATAAAACCCCTAGAAGAAAACCTAGGCATTACCATTAGGACATAGGGCTGGGCAAGGACTTCATGTCCAAAACACCAAAAGCAA  
TGCCAACAAAAGACAAAATTGACAAATGGGATCTAATTAACATAAAGAGCTTCTGCACAGCAAAAAGAACTACCATCAGAGTGAACAGGCAAC  
CTACAACATGGGAGAAAATTTTGAACCTACTCATCTGACAAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAATTTACAAGAAAAA  
ACAAACAACCCCATCAAAAAGTGGGCGAAGGACATGAACAGACATCTCTCAAAGAAGACATTTATGCAGCCAAAACACATGAAGAATGC  
TCATCATCACTGGCCATCAGAGAAATGCAAATCAAACCACTAGATATCACTCTCACACCAGTTAGAAATGGCAATCAAAAAGTCAGGAAA  
CAACAGGTGCTGGAGAGGATGCGGAGAAAATAGGAACCTTTTACTGTTGGTGGGACTGTAACCTAGTTCAACCATTGTGAAGTCAAGTGT  
GGCGATTCTCAGGGATCTAGAAGTAAATACCATTGACCCAGCCATCCATTACTGGGTATATACCCAAATGAGTATAAATCATGCTGCTAT  
AAAGACACATGCACACGTATGTTATTGCGGCACTATCAACAATAGCAAGACTTGGAAACCAACCAAAATGTCACAACATGATAGACTGGATTA  
AGAAAATGTGGCACATATACACCATGGAATACTATGCAGCCATAAAAATGATGAGTTCATATCCTTTGTAGGGACATGGATGAAATGGAACCC  
ATCATTCTCAGTAAACTCGCAAGAACAAAAACCAACCCGATATCTCACTCATAGGTGGGAATTGACAATGAGATCAGATGGACACA  
GGAAGGGGAATATCACACTCTGGGACTGTGGTGGGTCGGGGAGGGGAGGGATAGCATTGGGAGATATACCTAATGCTAGATGACAC  
ATTAGTGGGTGCAGCGCACAGCATGGCACATGTAAACGACGGATCGATCCGAACAACGACCCAAACCCCGTGGCTTTTATTCTGCTTT  
TTATTGCCGATCCCTCAGAAGAACTCGTCAAGAAGGGATAGAAGGGATGCGCTGCGAATCGGGAGCGGGATACCGTAAAGCACGA  
GGAAAGCGGTGAGCCATTCGCCGCAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGCTCTGATAGCGGTGCGCCGCTTTACTTG  
TACAGCTCGTCCATGCCGAGAGTATCCCGCGCGGGTACGAACTCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTGCTC  
AGGGCGGATGGGTGCTCAGTGTGGTGTGCGGACGACGACGGGCGCTGCGCGATGGGGGTGTTCTGCTGTAGTGTGGTGGCC  
GGTGAAGTCCAGGAGATCTTCCAGCACTGTTGCCCTTAGTCTCGAGGCAACTAGACAACCTGAGTATTGATCTGAGCACAGCAGGGTGTGAGC  
TGTTTGAAGATACTGGGTTGGGGTGAAGAACTGCAGAGGACTAAGTGGGCTGAGACCCAGTGGCAATGTTTAGGGCCTAAGGAATGC  
CTCTGAAAATCTAGATGGACAACCTTTGACTTTGAGAAAAGAGAGGTGGAATGAGGAAAATGACTTTTCTTTATTAGATTTCGGTAGAAAAGAC  
TTTTCATCTTTCCCTATTTTGTATTCTTTTAAACATCTATCTGGAGGCAAGGACATGATGGTATAAAAAGATGCAGGCAGAAAGGCATATA  
TTGGCTCAGTCAAAGTGGGAACTTTGGTGGCCAAACATACATTGCTAAGGCTATTCTATATCAGCTGGACACATATAAAATGCTGCTAATGC  
TTATTACAACCTTATCTTTAATCCAGATGGGGCAAAGTATGCCAGGGGTGAGGAAACATTTGAAACATTTGGGCTGGAGTATTTTGA  
AAAGTCAGCTGT  
GTTTTAGCCTACAGCATAACAGGTTTATGGTGGCAAGAAGATAACAAGATTTAAATTTAGCCAGTGACTAGTGTGCAAGAAGAACACTAC  
CTGCATTTAATGGAAAGCAAATCTCAGGCTTTGAGGGAAGTTAACATAGGCTTGTATCTGGGTGGAAGCTGGGTGTGTAGTTATCTGGAGG  
CCAGGCTGGAGCTCAGCTCACTATGGGTTTATCTTTATTGTCTCTTTTATCTCAACAGCTGCACCGTCCGCTCTCGATGTTGTGGCGG  
ATCTTGAAGTTACCTTGATGCCGTTCTTCTGCTGTGCGGCGATGATATAGACGTTGTGGCTGTTGTAGTTGACTCCAGCTGTGTGGCCCA  
GGTTGCGCGTCCCTTGAAGTGCATGCCCTCAGCTCGATGCCTTACCAGGGTGTGCGCCCTGCAACTCAGCAGCGCGGGCTTT  
GTAGTTGCCGTCGCTCTTGAAGAAGATGGTGGCTCTCGACGTAGCTTCCGGCATGGCGGACTTGAAGAAGTCTGTGCTCATGTG  
GTCGGGGTAGCGGCTGAAGCACTGCACGCGTAGGTGAGGTGAGGTCAGGAGGTTGGCCAGGGCACGGGCAGCTTCCCGTGGTGC  
GATGAACCTCAGGGTCAAGTTCGCTAGGTGGCATGCCCTCGCCCTGCGCGACACGCTGAACTTGTGGCCGTTTACGTCGCGCTCA  
GCTCGACCAAGGATGGGACCAACCCCGTGAACAGCTCCTCGCCCTTGTCTACCATGGTGGCGAATTGGAAGCTTGAGCTCGAGATCTGAG  
TCCGGTAGCGTACCGGATCTGACGGTCACTAAACCACTCTGCTTATATAGACCTCCACCGTACACGCCTACCGCCATTTGCCTCAATG  
GGCGGGAGTGTAGCAGATTTTGAAGTCCCGTATTGTTGGCCAAAACAACTCCATTTGACGTCAATGGGTGGAGACTGTAAGTGAAT  
CCCCGTGAGTCAAAACCGCTATCCAGCCCATTTGATGACTGCCAAAACCGCATCCATGTAATAGCGATGACTAATACGATGACTACTGC  
CAAGTAGGAAAGTCCATAAGGTCATGACTGGGCATAATGCCAGGCGGGCCATTACCCTGATGACGTCAATAGGGGGCTACTTGGCATA  
TGATACACTTGTACTGCCAAGTGGGCAGTTTACCCTAAATACCTACCCATTGACGTCAATGGAAGTCCCTATTGGCGTTACTATGGGAA  
CATACGTATTATTGACGTCATGGGCGGGGGTCTGGGCGGTGAGCCAGGCGGGCCATTACCCTAAGTATTGTAACCGGAACTCCATA  
TATGGGCTATGAACATGACCCGTAATTGATTACTATTAGCCGGGCAATGTGCACATGTACCCTAAAACCTAAAAGTATAATAAGACGTCAG  
GGTTCGAAATCGATAAGCTGGATCCAGACATGATAAGATACATTGATGATTTGGACAACCAACTAGAATGCAGTGAAAAAATGCTTTAT  
TTGTGAATTTGTGATGCTATTGCTTTAATTTGTAACCATATAAGCTGCAATAAACAAGTTAAACAACAATTTGCAATCATTTTATGTTTCAAGTT  
CAGGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTAAACCTCTACAATGTGGTATGGCTGATTATGATCCGGCTGCCTCGCGGTTTTCGGT  
GATGACGGTGAACCCCTGACACATGCAGCTCCCGGAGACGGTACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAG  
GGCGCTGACGGGTGTTGGCGGTGTCGGGGCGCAGCCATGAGGTGATGACTCTAGAGGATCGATCCCGCCCGGACGAACTAAA  
CCTGACTACGACATCTGCCCCCTTCTCGCGGGCAGTGCATGTAATCCCTCAGTTGGTGGTACAACCTGCAACTGGGCCCTGTTCCA  
CATGTGACACGGGGGGGACCAAAACAAAAGGGTTCTCTGACTGTAGTTGACATCCTATAAATGGATGTCACATTTGCCAACACTGAGT  
GGCTTTCATCTGGAGCAGACTTTGCACTGTGGACTGCAACAACAATTGCCCTTTATGTGTAACCTTTGGCTGAAAGCTTTACACCAATGC  
TGGGGGACATGTACTCCCAGGGGCCAGGAAGACTACGGGAGGCTACACCAACGTCATCAGAGGGGCTGTGTAGCTACCGATAAGCG  
GACCCCTAAGAGGGCATTAGCAATAGTGTATAAGGCCCTTGTAAACCTAAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATC  
CAGACTAACCCATAATCAATAGCATATGTTACCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGCTCCTAAGGAACAGCGATATC  
TCCCACCCATGAGCTGTACCGTTTTTATTTACATGGGGTCAAGATTCCACGAGGGTAGTGAACCTTTTAGTACAAAGGGCAGTGGCTGAA  
GATCAAGGAGCGGGCAGTGAACCTCTCGCTGCTTCTGATTTGACATCCTTATAAATGGATGTCACATTTGCCAACACTGAGTGTGAACA  
GTAAGGTGTATGTGAGGTGCTCGAAAACAAGTTTTCAGGTGACGCCCCAGAAATAAAATTTGACGGGGGTTCAAGTGGTGCATTGTGCTA  
TGACACCAATATAACCCCTCACAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTTGAAATATCTTTAACAATAGAATCCATGGGG  
TGGGACAAAGCCGTAAGACTGGATGTCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGAATATGATACTGGGGTATT  
AAGATGTGCCAGGCGAGGACCAAGACAGGTGAACCATGTTTACTACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAG  
CGGACTCCAAGTGTCTTAACACCCCGAAAATTAACGGGGCTCCACGCCAATGGGGCCATAAACAAGACAAAGTGGCCACTCTTTT



CCTGTCATACTTTGTTAAGAAGGGTGAGAACAGAGTACCTACATTTTGAATGGAAGGATTGGAGCTACGGGGGTGGGGGTGGGGTGGGATTA  
GATAAATGCCTGCTCTTTACTGAAGGCTCTTTACTATTGCTTTATGATAATGTTTCATAGTTGGATATCATAATTTAAACAAGCAAAACCAAATTA  
GGGCCAGCTCATTCCCTCCCACTCATGATCTATAGATCTATAGATCTCTCGTGGGATCATTGTTTTCTCTTGATTCCCACCTTTGTGGTTCTAAGT  
ACTGTGGTTTCCAAATGTGTCAGTTTCATAGCCTGAAGAACGAGATCAGCAGCCTCTGTTCCACATACACTTCATTCTCAGTATTGTTTTGCCA  
AGTTCTAATTCATCAGAAGCTGGTCGACATTGGATTGGAAGTAGTATACTAACCTTCACCTATTGCAATTCATGTTTGACAGCTTATCATCG  
CAGATCCGGGCAACGTTGTTGCCATTGCTGCAGGCGCAGAAGCTGGTAGGTATGGAAGATCTATACATTGAATCAATATTGGCAATTAGCCATAT  
TAGTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAA  
TATGACCGCCAT

**13.2 pCEP4 L1RP-ENm (H230A) (L1RP-ENm) and pCEP4 L1RP-RTm (D702Y) (L1RP-RTm) plasmids** share the same sequences as pCEP4 L1RP except for the following minor key changes:

|                        | EN (3362-3364 bp) | RT (4778-4780bp) |
|------------------------|-------------------|------------------|
| pCEP4 L1RP             | H230 (CAC)        | D702 (GAC)       |
| pCEP4 L1RP-ENm (H230A) | A230 (GCC)        | D702 (GAC)       |
| pCEP4 L1RP-RTm (D702Y) | H230 (CAC)        | Y702 (TAT)       |